CA2240843A1 - Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same - Google Patents
Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same Download PDFInfo
- Publication number
- CA2240843A1 CA2240843A1 CA 2240843 CA2240843A CA2240843A1 CA 2240843 A1 CA2240843 A1 CA 2240843A1 CA 2240843 CA2240843 CA 2240843 CA 2240843 A CA2240843 A CA 2240843A CA 2240843 A1 CA2240843 A1 CA 2240843A1
- Authority
- CA
- Canada
- Prior art keywords
- rotavirus
- strain
- virus
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A process for producing rotavirus antigens characterized by cloning, from cultured cells, those allowing an ample growth of rotavirus which can be hardly cultured on a large scale, subculturing and conditioning the rotavirus in the cell clone strain thus obtained to thereby give a cell clone-conditioned rotavirus strain, culturing as a seed virus this strain or a reassortant constructed by using the same as the parent strain, and then isolating and purifying a rotavirus antigen from the culture; and vaccines and diagnostic drugs for infection with rotavirus produced by using these antigens. These antigens, vaccines and diagnostic drugs largely contribute to fundamental studies and clinical application relating to infection with rotavirus.
Description
ROTAVIRUS ANTIGEN, VACCINE AND DIAGNOSTIC AGENT FOR
ROTAVIRUS INFECTIONS, AND A METHOD FOR PRODUCING THE ANTIGEN
Technical Field The present invention relates to rotavirus antigens of which themassproductionvia cell culturearedifficult,avaccine against rotavirus infections and a diagnostic agent of the diseases and methods for producing the same. More specifically, the present invention relates to a vaccine and a diagnostic agent useful for the prophylaxis and diagnosis of rotavirus infections, and rotavirus antigens as the effective ingredient thereof. The present invention makes contributions to the prophylaxis and ~i~gno~is of rotavirus infections in humans, in particular.
Background Art Rotavirus is a pathogenic microorganism causing diarrhea inhumans,monkeys,dogs,cats,horses, cows,pigs,sheep,rabbits, rats, chickens, turkeys and the like, and is widely distributed all around the world. Rotavirus infections in humans in particular have been drawing attention, as vomiting and diarrhea in babies, winter-tenm diarrhea in babies, diarrhea with white feces, kid pseudo-cholera and the like. The prophylaxis and diagnosis thereof have been expected strongly at a worldwide scale.
What will be described below has been known concerning rotavirus.
~o~hol ogy and gename structure According to the6-th reportby theInternationalCommittee of Taxon~myofViruses, thevirusbelongs to the family Reoviridae, and is in an exact icosahedron of a diameter of about 70 nm, comprising a double capsid structure of inner and outer capsids (three layers in total, including the int~rm~i~te layer) with no envelop, and has a core of a diameter of about 50 nm at the center of the inner capsid. Inside the core is present a genome, comprising alin~r double-stranded RNA with 11 segments, and the sizes of these genome segments are within a range of 0.6 to 3.3 kbp ("~irus Taxonomy: Sixth Report of the International C~m--mittee of T;~ n~lmy of Viruses", Archives of Virology, Supplement 10, pp.219 - 222, 1995).
Genotype and serotype From the standpoint of developing a vaccine and a diagnostic agent therefor, attention has been focused particularly on the fourth genome segment and the ninth genome segment (corresponding to the seventh or eighth genome segment in some strain), among the 11 genome segments described above.
Rotavirus strains isolated worldwide have been classified into six groups (serogroups) from A to F and each group is divided into various serotypes; for convenience, additionally, rotavirus strains are broadly grouped depending on the genotypes. These isolated strains have a variety of both antigenicities and genotypes ("Fields Virology", 3rd ed., vol.l2, pp.l625 - 1629, edited by B. N. Fields et al., Lippincott-Raven Publishers, 1996, 5 USA). The following description is about what is described ;mm~t~i~tely above.
The fourth genome segment encodes the structure protein VP4 exposed in a spike form on the surface o~ the virus particle, and it is reported or assumed that VP4 may functionally be involved 10 in blood cell agglu~i ni n.C, neutralizing antigens, the infectivity promoted by protease, pathogenicity, membrane fusion, adsorption to cells, and so on. Based on the arnino acid sequence of the VP4 and the homology with the RNA or cDNA of the gene, rotavirus stains are currently classified into 20 genotypes (referred to as "P
15 genotype" hereinbelow); and based on the neutr~li 7i ~tg test, rotavirus strains are also classified into 10 or 14 serotypes (referred to as "Serotype P" hereinbelow).
The ninth genome segment (seventh or eighth genome segment in some strain) encodes the outer capsidVP7 o~ the virus particle, 20 and it is reported or assumed that the VP7 may possibly function to retain the epitope of neutralizing antigen and two hydrophobic regions. Based on the neutralizing test o~ the VP7, rotavirus strains are classified into 14 serotypes (referred to as "serotype G" hereinbelow).
25 Classi~ication o~ rotavi~us strains Among a great number of various isolated strains reported previously ("Fields Virology", 3rd ed., vol.2, p.l627), a typical human rotavirus strain of the group A and the following strains isolated and reported by the present inventors, namely AU-l 5 (Journal of Clinical Microbiology, 25, 1159 - 1164, 1987), AU32 (MicrobiologyandImmunology, 34, 77-82, 1990) andAU64 (Archives of Virology, 19, 67 - 81, 1991), are broadly classified as follows in Table 1.
Table 1 Name of strain Serotypes G and P tgenotype]
Wa GlPlA[8]
DS-l G2PlB[4]
P G3PlA[8]
A~-1 G3P3 [9]
Hochi G4P~A[8]
ST3 G4P2A[6]
AU32 G9PlAt8]
AU64 GlPlB[4]
Detection ~requency of~ serotype According to about20 research reports worldwide about the detection frequency of the serotype G of rotavirus, type Gl is main, occupying about 60 to 85 % in Japan, European countries, Australia and Central Africa and the like, while the remaining partisprimarilyoccupiedby types G2 andG3. InIndia, Thailand, Bangl~ h, Mexico and the like, alternatively, Gl, G2 G3 and G4 are detected in a sporadic fashion, and the ratio of them in total ranges at about 20 to 80 %, and the sporadic occurrence of other types except these types is also observed prominently.
virus culture Because rotavirus isolated from monkeys and cattle is generally grown in a culture cell in a relatively ready manner, the culturing or passages thereof is not essentially hard.
However, so-called abortive infection occurs during the passage of human rotavirus in cell culture, characteristically involving the generation of a virus antigen impossible of serial passages for obtaining the infectious virus particle, and therefore, the virus p~C~geis very hard. Hence, aprocedure has been designed, comprising preparing a reassortantbetween a human rotavirus with a low growth potency and a monkey- or cow-derived rotavirus with a high growth potency, to improve the growth potency of human rotavirus, or comprising inoculating a human rotavirus pr~l imin~rily treated with trypsin into a monkey-derived cell strain MA104 (ECACC No. 85102918) and AGMK (African Green Monkey Kidney) cells, and thereafter injecting the rotavirus to the roller tube culture using a maintenance medium supplemented and mixed with trypsin. Currently, almost all human rotaviruses of the group A can directly be cultured or isolated in laboratories.
However, even through the above roller tube culture, a virus antigen at an amount required for the production of vaccine or diagnostic agent cannot be recovered. Still currently, the culturing or passaging of rotaviruses except the viruses of the group A is at a very difficult stage.
Host of virus culture For the culturing of permissive cells permitting the proliferation of rotavirus, the following individual cell strains have been known, other than the MA104 and GMK cells; individual cells of FBK (fetal bovine kidney), CMK (cercopithecus monkey kidney), MK (crab-eating macaque kidney), etc.; individual cell 10 strains of monkey-derived CV-1, FRh L2, BSC-l, and Vero cell and dog-derived MDCK, human intestinal epidermis-derived CaC0-2, etc.
(WO 92/01784, Japanese Patent Laid-open No. 06-328107, the "Fields Virology", 3rd ed., vol.2, pp.1647 - 1648, pp. 1661 - 1162). For the mass production of rotavirus antigen for the purpose of 15 pro~ ~i n~ a vaccine, furthermore, cell strains for use in pro~ ;ng other virus vaccines, such as Vero, DBS-FLC-1, DBS-FLC-2, DBS-FRh L2, ESK-4, HEL, IMR-90, MRC-5, MRC-9, WI-38, and WRL68, can be utilized ~"ATCC Microbes & Cells at Work/', 2nd ed., p.144, A~Lerican Type Culture Collection 1991, USA).
Vaccine Various vaccines against human rotavirus infections have been attempted and developed since around 1985. The main stream lies in the development of a live vaccine by so-called Jennerian 25 approach, wherein a non-human-derived attenuated vaccine with a similar antigenicity is used as vaccine in place, like small pox vaccine; for example, it has been known clinical trials of live vaccines by using a cow- or monkey-derived attenuated v~c~in~ or an attenuated reassortant between two virus strains each derived from both humans and cow or from both humans and monkeys (WO
92/01784; EPO 130906; J~p~n~e Patent Laid-open No. 06-328107;
"Modern Vaccinology", pp. 213 - 229, edited by E. Kurstak, Plenum Medical Book Company 1994, USA; "Vaccines", 2nd ed., pp. 809 -822, edited by S. A. Plotolokin and E. A. Mortimer, W. B. Saundors ~ 10 Company 1994, USA; "The Jordan Report - Accelerated Development of va~in~s 1996~, p. 46 and p.68, National Institute of Health issued, USA). As the data of the clinical trials of these live vaccines or the oral dosing thereofhas been~ ml~l~ted, however, it has been remarked increasingly that the prophylactic effect is notsufficient. Currently, therefore,an attempthasbeenmade for the production of a vaccine based on a different idea from the idea of the Jennerian approach.
Diagnostic agent Antigens are mainly detected withpolyclonal or monoclonal antibodies, and kits for EIA (enzyme immllno~Say), ELISA
(enzyme-linked immunosorbent assay), latex agglutination and passive hemagglutination, for example, are now c~mm~rcially av~ hle. Diagnostic methods at gene levels by means of PAGE-SS
(polyacrylamide gel electrophoresis with silver stain), PCR
(polymerase chain reaction) and the like are now developed ("Principles andPracticeofInfectiousDiseases",4thed.,vol.2, pp. 1450 - 1451, edited by G. L. ~n~l 1 et al., Churchill Livingstone 1995, U5A). Because no diagnostic agent by means of virus antigens for antibody detection has been distributed yet, data relating to the temporal variation of various antibodies against rotavirus antigens in patients is still likely to be insufficient, although such data is extremely useful for the elucidation of rotavirus infections and the count~rm~cure thereof including prophylaxis and therapeutic treatment.
Insuch circumstance~onc~rninghuman rotavirusashasbeen described above, the present invention has been attained. It is an object of the present invention to overcome the current stage such thatthemassproductionofrotavirus antigenviacell culture is very difficult, and provide a method ~or producing a rotavirus antigen at a large scale, the antigen being required for producing a v~i n~ against rotavirus infections, and a diagnostic agent of the diseases.
It is the other object of the present invention to provide the antigen recovered by the method described above, a vaccine against rotavirus infections and a diagnostic agent of the diseases, which are to be produced by using the antigen.
Disclosure of the Invention So as to overcome the problems, the present application provides the following inventions.
More specifically, a first aspect of the present invention is a method for producing a rotavirus antigen, comprising cloning a cell highly permitting the proliferation of rotavirus from a cell culture; preparing a cloned cell adapted-rotavirus strain by passaging a rotavirus in the resulting cloned cell strain and adapting the rotavirus to the cloned cell strain; culturing as a seedvirus theadaptedrotavirusstrain ora reassortantprepared - 10 ~y using the adapted rotavirus strain as a parent strain; and isolating and purifying the rotavirus antigen from the culture medium of the seed virus.
In a preferable embodiment of the first aspect of the present invention, the culture cell is Vero cell (ATCC CCL 81).
In another pre~erable embodiment of the first aspect of the present invention, the cloned cell strain is Vero CL-9 (FERM
BP-6028).
As a still other preferable embodiment of the first aspect of the presentinvention, the rotavirus is human rotavirus strain AU32n and/or AU64n.
A second aspect of the present invention is the rotavirus antigen recovered by the aforementioned method.
A third aspect of the present invention is an inactivated antigen prepared by further inactivating the rotavirus antigen of the second aspectof the presentinvention with an inactivator.
A fourth aspect of the present invention is a vaccine against rotavirus infections, the v~; n~ containing the rotavirus antigen of the second aspect of the present invention or the inactivated antigen of the third aspect of the present invention at an amount for causing an immune response.
A fifth aspect of the present invention is a c~mh; n~
multivalent vaccine for rotavirus infections, containing two or moreantigensatan amountrequiredforanimmlln~response~wherein the antigens are the rotavirus antigen of the second aspect or the inactivated antigen of the third aspect and the serotypes or genotypes thereof are different from each other.
A sixth aspect of the present invention is a diagnostic agent, containing the rotavirus antigen of the second aspect or the inactivated antigen of the third aspect at an amount required for an antigen-antibody response.
A seventh aspect of the present invention is a cloned cell strain Vero Cl-9 (FERM BP-6028).
An eighth aspect of the present invention is a cloned cell adapted-human rotavirus strain A~32n.
A ninth aspect of the present invention is a cloned cell adapted-human rotavirus strain AU64n.
In this application, the term "cloned cell strain" means a culture cell of a clone singly composed of theprogeny ofasingle cell (species).
The term "adaptation" means the promotion of the mutation or selection of virus proliferation potency to fit the proliferation potency to the purpose, so that a virus mass production mightbepossibleunder constant conditions of the cell type and temperature for virus culture. For example, a virus adapted to a certain cell can proliferate well in the cell and a virus adapted to low temperature can proliferate well at the low t~r~rature~
~ le term "permissive" means the "permissive" property of a cell to permits virus proliferation. For example, the tenm "rotavirus permissive cell" means that rotavirus can proliferate or can be cultured in the cell.
~ le term "cloned cell-adapted virus strain" means a virus which is adapted to a cloned cell strain, by serial passages of the virus in the said cloned cell strain.
Other terms are apparently shown in the following description of the best mode for carrying out the invention.
Best Mode ~or Carrying out the Invention Each invention in this application can be practiced, by carrying out the following ~irst to ~ourth processes.
First process: cloning a cell highly permitting the proliferation of rotavirus, namely highly permissive cell, frQm a cell culture.
Second process: preparing a cloned cell adapted-rotavirus strain which is adapted to the cloned cell strain recovered at the preceding process, under serial passages of the virus in the cloned cell strain, namely an adapted rotavirus strain ~p~hl e of extremely actively or highly proliferating in the cloned cell strain. If n~, a reassortantis preparedby using the adapted rotavirus strain as a parent strain. The rotavirus to be used at the first process is not necessarily the same as the rotavirus cultured at the second process.
Third process: mass producing rotavirus antigens, namely complete rotavirus particle, incomplete rotavirus particle, - -- 10 antigenic protein, genome, gene and the like, by culturing as a seed virus the adapted strain or the reassortant recovered at the preceding process.
Fourth process: preparing and producing vaccines, diagnostic agents, and reagents and the like, by purifying, processing or modi~ying the complete rotavirus particle, incomplete rotavirus particle, antigenic protein, genome, gene and the like, as recovered at the pr~ ng process.
The processes are now described below sequentially in the order.
Culture cell to be used at the ~irst process As the subjective culture cell for cloning a cell highly permitting the proliferation of rotavirus, use is made of various cells or cell strains as previously described in the section of the "Hostforvirus culture"in theBackgroundArt. Foruse, then, a culture cell in which the absence of adversely affecting cont~min~ted factors or cancer genes is concluded, for ~m~le Vero cell (ATCC CCL 81), is preferably used.
l~otavirus for use at second process As the rotavirus tobepassagedin and adapted to the cloned cell strain reGovered at the aforementioned process, use is made ofisolatedstrainsdescribedin thereference ("Fields Virology", ~ 3rd ed., vol.2, p.l627, Archives of Virology, 19, 67 - 81, 1991, - 10 etc.) or appropriate rotavirus strains. Particularly, a strain to be passaged during cell culture with much di~ficulty or a virus strain promising for the increase of the production o~ antigens is pre~erable. For ~7~rle, known strains o~AU-l, AU32 andAU64, and novel human rotavirus strains with an appropriate passage history as a virus strain for vaccine production, such as AU32n and AU64n, which are to be provided in accordance with the present invention, are preferable.
Cell culture medi7m, and m~7;77m ~or virus growth Known and c~mm~rcially av~ hle media, for example 199 medium,MEM (Eagle's~i ni mllm Essential Medium),BME (Eagle'sBasal Medium), Hanks solution, andDulbecco's phosphatebufferedsaline (PBS), may be used. The compositions and preparative methods thereof are described in detail in general texts relating to virus experiments, cell culture and tissue culture (for example, "Cells & Tissue Culture; T~horatory Procedures", 2 volumes in total, editedby A.Doyle etal., JohnWiley &Sons 1993,USA) and catalogs of c~mm~rcially available products. Such media and salt solutions may be supplemented and modified with auxiliary agents or additives. As the additives, use may be made of routine subst~n~s;itisselectedfrom forexample~mm~rciallyav~ hle human serum, fetal calf serum, antibiotics, sodium hydrogen carbonate,sodiumchloride, non-essential aminoacids and thellke, for use at an appropriate amount. For example, the final concentrations of the a~itives to be added and mixed with one liter of a culture medium are as follows; sera at about 3 to 25 %
(V/V);sodiumhydrogen carbonate ataboutl to 6g;sodiumchloride at about 0.1 to 0.25 mole; and non-essential amino acids at standard amounts as described in the product catalogs. It has been known that protease or trypsin in particular is preferably added and mixed into rotavirus proliferation media. Herein, the final trypsin cQ~c~ntration in the media for rotavirus growth is about 0.1 to 10 ~ g/ml.
20 Cell culture and cell ~-70n;n~
The passage of a cell strain generally comprises preparing a cell suspension ataboutlX105- 4X105cells/ml ina cell culture medium, and passaging the suspension of a volume about 1/10 to 1/5-fold the volume of a culture container, for example about 10 25 - 20 ml in a 100-ml container and culturing then the cell at about 37 ~C. So as to peel off cells having formed a m~nocheet on the bottom of the container from the area of the culture container and then disperse the cells, generally, use is made of a trypsin solution of about 0.25 % (W/V) as the final co~ntration~ which is preliminarily prepared in PBS fram which both Ca and Mg ions are eliminated.
According to the routine method ("Cells & Tissue Culture;
LaboratoryProcedures",vol.1,pp.4B:3,supra.),cellsarecloned Cell cloning may satisfactorily be effected, for ~mple~ by a method (colony forming method) for preparing a clone singly composed of the progeny of a single cell, comprising peeling off a monosheet of cultured cells in the trypsin solution and dispersing the sheet in the cell culture medium to prepare a suspension of a free cell (aboutl to 5 cells/ml), theninoculating the suspension into culture cont~i n~S, for example petri dish or microtest plate, for culturing. Recovered colonies are independently cultured to increase the cell number, whereby a cloned cell or a cloned cell strain can be recovered.
20 Virus c1lltu:ring and passage and adaptation The temperature for virus culture in a hostof cell culture is generally about 20 to 37 ~C, and the culture duration is about 2 to 16 days. Stationary culture or roller tube culture may satisfactorily be used. The supernatant of the culture fluid after culturingissubjectedtoviruspassageas avirussuspension .~ .. _- - . . .
.~.
Virus passaging is effected by sequentially inoculating virus suspensions in fresh culture cells to proliferate the virus. By repeating the virus passaging in a specific cell about 2 to 50 times, preferably about 3 to 20 times, a specific cell-adapted 5 virus strain very highly proliferating in the cell can be recovered By preparing a reassortant between the adapted virus strain as the parent strain and another virus strain, the high proliferation potency of the adapted virus can be transferred into a different virus strain. E~y mi7ci ng together a rotavirus strain inactivated - - 10 with the irradiation of ultraviolet ray (W) and the adapted virus strain (parent strain) and culturing themixture, thereby in~ ~ing the reassortment of the genome segments of the viruses of both the strains, and eliminating the parent strain virus with an anti-parent strain neutralizing antibody, a r~m~i n i ng infectious 15 virus can be recovered as a reassortant.
Selection o~ highly p~m; c~ ;ve ~on,~l cell strain ~or rotavirus By inocula'cing and culturing rotavirus in each cloned cell, the numbers of infectious viruses and virus particles or the level 20 of virus antigen, which are generated through the virus proliferation, is det~ined. In this case, it is i-m$~ortant to determine the extent of the proliferation due to the difference in ~I (multiplicity of infection), namely so-called virus production level, high or low, depending on the difference in virus 25 inoculation level, by a method described below. By screening a cloned cell in which the virus can highly proliferate by using such measured values as markers, a highly permissive cloned cell strain can be yielded. The measurement is done by plaque forming method (counting PFU (plaque forming unit)), focus forming method (counting FFU (focus forming unit)), ELISA, IME(immune electron microscopy) and the like. Herein, FFU is counted by fluorescent antibody technique comprising staining an infectious cell region formed due to the infection and proliferation of the virus with a fluorescent dye FITC (fluorescein isothiocyanate)-labeled antibody, by EIA (enzyme immunoassay) and the like.
Mass production and preparation ol~ virus and antigen By using a cell culture o~ a highly permissive cloned cell strain as a host and culturing a virus strain adapted to the cell strain, the virus and an antigen are produced at a large scale.
More specifically, after the termination of culturing, a supernatant of a virus culture fluid after centrifugation at a low speed (for example, a supernatant of a suspension of a virus infected cell after freezing and thawing in dry ice and an organic solvent) is collected, to prepare a complete virus particle and the antigen. Such preparation may be used as the virus suspension as it is. The suspension is possibly disinfected by membrane filtration, or antibiotics may satisfactorily be added to the suspension. The virus antigen in the suspension and the like may be concentrated and purified by membrane concentration, density gradient ultra-centrifugation, ultra-centrifugation on a sucrose cushion. The virus suspension is overlaid on a sucrose solution as a cushion, for example, for subsequent ultra-centrifugation, to precipitate the virus antigen on the bottom of a centrifuge 5 tube, and the precipitate is again susp~n~ to prepare a purified virus antigen.
Preparation of ~ v~ ; ne b2l1k solution A vaccine bulk solution can be prepared by using the virus - 10 suspension or purified virus antigen. As the antigen for vaccine, furth~rTn~e, use may be made of complete virus particles, incomplete virus particles, protein of the virion structure for r~le VP4 and VP7, neutralizing reaction epitope region, and modified structural protein after translation and the like in the 15 virus suspension, andprotein of non-virion structure andmodified protein after translation, and protective antigens against infection and the like. Such antigens for vaccine can be iTTm~hilized with inactivating agents, so that the steric structure can be st~hilized As the inactivating agent, for example, use 20 maybemadeof formalin, phenol, glutaraldehyde, B-propiolactone and the like, which are added into a vaccine bulk solution prior to or after the preparation of the solution. If used, fo~n~li n is added at an amount of about 0.005 to 0.5 % (V/V), and the inactivation temperature is about 2 to 38 ~C and the inactivation 25 time is about 5 to 180 days. When the antigenicity is deteriorated through such inactivation, however, an instrumental measure is required formodi~ying theinactivation conditions, including for example the reduction of the amount o~ the inactivator, the a~;tion of neutral amino acid or basic amino acid, and the lowering of the inactivation temperature. The ~ree formaldehyde r~m~;ni ng at the inactivationprocess canbe neutralizedby adding an equal amount of sodium hydrogen sulfite or can be ~limin~ted during dialysis. The preparation thus produced is subjected to the following process as a vaccine bulk solution.
Preparation o~ vaccine The vaccine bulk solution is diluted for example in a culture medium BME, to adjust the antigen level in the vaccine to the level required for antibody generation.
Then, a stabilizer for enhancing the heat resistance of the vaccine or an adjuvant as an a~ ry agent for e~h~n~ing the immunogenicity, may be added and mixedinto the bulk solution.
For ~m~le~ use may be made of sugars and amino acids as st~hilizers; and mineral oil, vegetable oil, alum, aluminum phosphate, bentonite, silica, muramyl dipeptide derivatives, thymosin, interleukin and the like as auxiliary agents.
For the purpose of the induction of mucosal immllnity or local immllnity~ the virus antigen in the vaccine bulk solution may be treated or modified. For the induction, a technique relating toDDS (drug delivery system) using for exampleliposome, emulsion, microcapsule, microsphere, polylactic acid, and polyglycolic acid is applicable.
Then, the v~c~i~ solution is divided into a vial of an appropriate volume, for example about 1 - 20 ml, followed by stopping and sealing, and the resulting vaccine solution is subjected to use. The vaccine is not only at a liquid state but is also subjected to use as a dry formulation by freeze-drying the solution after division. For the purpose of oral administration, the vaccine solution is possibly processed into for example syrups or candies.
$o as to guarantee the quality prior to use, namely during the production processes thereof and at the division stage of the solution in small portions, the prepared v~c~;n~ form~ tion is testedas to thesafetyandefficacy, toverify theappropriateness of the solution as vaccine. Such testing can be practiced following the standard for a formulation similar to the rotavirus vaccine of the present invention, for example, the Regulation "Inactivated Acute Polymyelitis Vaccine Standard" defined in "Biological Formulation St~n~rd" according to the Ph~rm~utical Law (Law No.145, 1960) and Notification No.315, 1960 of theMinistry ofHealthandWelfareandNotificationNo.337, Revision, 1961 of the Ministry of Health and Welfare; both the Regulations "Japanese B Encephalitis Vaccine" and "Dry Japanese B Encephalitis Vaccine" as defined in the "Biological Formulation St~n~rd" according to the aforementioned Pharmaceutical Law and Notification No.217, 1993 of the Ministry of Health and Welfare;
or the Regulation "Dry TissueCulture Inactivated Type AHepatitis Vaccine" defined in the "Biological Formulation Standard" according to the aforementioned Ph~rm~c~lltical Law and Notification No.332, 1994 of the Ministry of Health and Welfare;
and the like.
Dosage of V~r~i n~
Vaccine inoculation is practiced, by inoculating the - 10 vaccine subcutaneously for example at a dose of about 0.25 to 0.5 ml; by orally administering one dose of about 1.0 ml; or by injecting about 0.05 ml of the v~i n~ into oral cavity.
Furthermore,suchinoculationispreferablypracticedone tothree times at an inter~al of about 2 to 4 weeks. However, the vaccine dosage is not limited to the ~rles described above.
Preparation of~ n;~nostic agerlt In the same fashion as described above, a virus suspension or a purified antigen or the like is prepared, which is then provided as a diagnostic antigen (for example, antigens for precipitation reaction, agglutination reaction, neutralizing reaction, fluorescent antibody technique, enzyme immunoassay, radioimmunoassay, etc.). By inoculating the diagnostic antigen or the vaccine bulk solution periton~lly/ subcutaneously, intra-muscularly in animals (for example, r~hhit, guinea pig, mouse, etc.), antibodies may be prepared from the sera of the animals. The antibodies are provided for antigen assay by the various diagnostic methods described above. The diagnostic antigens and antibodies in accordance with the present invention are diluted and adjusted to an amount required for inducing antigen-antibody reaction, prior to use. Fur~h~-re, the genome and its cDNA fragment of rotavirus in accordance with the present invention may be provided Eor ~le as probe reagents and identification reagents for gene diagnosis.
The present invention will now more specifically be described in further detail in the following examples, but the invention is not limited to the ~mrl es.
~le 1 15 (1) Cell cloning Vero cell (ATCC CCL 81) was cultured in a cell culture mediumMEMsupplementedwith FCS (manufacturedbyGibco, Co., USA) at a final concentration of 9 % (V/V) in a container with a culture area of 25 cm2 at 37 9C, to form a monosheet. The monosheet was 20 peeled off in 0.25 % (W/V) trypsin (trypsin 1: 250; manufactured byDifco, Co., USA~I solution from the area of the culture container, to disperse the cells to prepare the cells into a free single cell, and thereafter, the cells were collected with centrifugation at a low speed (1500 rpm, 5 minutes), to prepare a suspension of a 25 free single cell at 2 cells in cell number/ml in the culture medium.
The suspension was inoculated in 0.2 ml portions into each well of a 96-well microtest plate (Falcon Microtest III Plate;
manufactured by Becton Dickinson, Co., U5A) and was then cultured in a CO2 incubator at 37 ~ for 14 days, to form a colony singly composed of the progeny of the single cell on the surface of each well. The cells in each o~ the individual colonies were sequentiallypassagedthreetimesintoalarger cont~; n~,thereby increasing the number of the cells, where~y 40 in total of cell suspensions of individual Vero cell colonies were recovered.
(2) Screening of rotavirus permissive cloned cell strain Rotavirus in each of the cloned cells in total of 40 as recovered above in (1) was cultured and proliferated, to assay the rotavirus antigen in the culture supernatant by ELI~A, and then, a cloned cell strain with a far higher antigen titer than the titer of the Vero cell prior to cloning was screened as described below in a) to c).
a) Culturing of virus in each cloned cell Each cloned cell was assigned to eight wells in one cross row of the microtest plate (96 wells; 8 wells in cross direction X12 wells in lengthwise direction), and then, 40 in total of the cell suspensions of individual clones were independently inoculated at 0.2 ml/well, for incubation at 37 &~, to form a monosheet of each clone. Subsequently, the culture fluid in each well was exchanged to a fresh MEM with no addition of serum for further culturing overnight. Into the cells in each well was added 0.05 ml/well of rotavirus AU64 strain fluid activated with trypsin treatment in a medium for virus growth described below (provided that the final trypsin concentration was 20 ~ g/ml) at 37 ~ for 20 minutes, and then, the cells were left to stand at 37 ~ for 30 minutes, so that the cells could adsorb the virus.
Thereafter, an MEM with addition of trypsin to a final concentration of 0.5 ~ g/ml as a medium for virus growth was added at 0.2 ml/well, for culturing and proliferating the virus at37 ~
for 7 days. After the termination of the culture, the culture fluid in each well was subjected as a virus suspension (sample) to the assaying of virus antigen described below. As a c~mr~rative control, herein, the Vero cell prior to cloning was used.
b) Assay of virus antigen (primary screening) The antibody against rotavirus of group A (IgG purified from per-immunized serum in guinea pigs) was diluted in 50 mM
carbonate buffer, pH 9.6, to prepare an antibody solution at a concentration of 1.0 ~ g/ml. The antibody solution was added at 0 1 ml/well into a 96-well test plate for ELISA (ELISA-PLATE;
manufactured by Greiner, Co., Germany), which was then left to standat4 ~ overnight, toadsorb theantibody on thewellsurface.
After adsorption, each well was rinsed in a rinse solution [PBS
containing Tween 20 at a final concentration of 0.05 % (W/V)].
Meanwhile, each virus suspension described above was diluted 5-fold in an antigen dilution solution [Block A~e (manufactured by Snow Brand Milk Industry, Co. Ltd.) was diluted by 10-fold in deionized water], and the resulting prepared samples each were added in 0.1-ml portions into each well, for primary reaction at 25 ~ for 90 minutes. After rinsing the wells with the aforementioned rinse solution, then, peroxidase-labeled anti-rotavirus goat antibody (manufactured by Viro Stat Co., USA) was diluted 2,000-fold in the antigen dilution solution, and the - 10 resulting antibody solution was added at 0.1 ml/well, for se~on~ryreaction, againat25 ~, for90minutes. Subsequently, each well was rinsed in the rinse solution, followed by addition of a substrate solution [0.5M citrate - phosphate buffer, pH 5.0, contalning o-phenyl~n~i ~mi ne (manufactured by Wako Pure Chemical Industries, Co.) at a final concentration of 0.4 mg/ml and an aqueous 35 % (V/V) hydrogen peroxide solution (Wako Pure Chemical Industries, Co.)] at 0.1 ml/well, for chromogenic reaction at ambient temperature for 10 minutes, followed by further 0.05 ml/well addition of 4N sulfuric acid to terminate the reaction. After the t~rmin~tion of the reaction, the absorbance (OD) of each well was counted at a monochromatic ray at a wave length of 490 nm. As the results of the aforementioned primary screening, six samples with OD of 5-fold or more the OD
of the ~m~rative control were selected, and the correspon~i ng cloned cell strains were thensubjected to the followingsecondary screening.
c) Assay of virus antigen (secondary screening) In the same manner as described above in (1), cells of the six cloned strains were cultured in a microtest plate, and simultaneously, the AU64 strain was cultured and proliferated in the cells in each well. So as to observe the extent of growth, depending on the difference in MOI, additionally, the virus suspension was serially diluted 4-fold, and each dilution series - - 10 was assigned to one row in the lengthwise direction and two wells in the cross row. Additionally, the virus antigen was assayed by ELI~A, in the same manner as for the primary screening.
Consequently, three highly permissive cloned cell strains highly permitting the proliferation of rotavirus couldbe recovered, and these strains were individually designated as Vero CL-9 (FERM
BP-6028), Vero CL-16 and Vero CI-81-7.
F.~rr~le 2 Adaptation of rotavirus:
Individual cloned cell strains recovered in Example 1, namely Vero CL-9, Vero CL-16 and Vero CI-81-7, were cultured at 37 ~ in a cell culture medium MEM [supplemented with FCS
(manufactured by Gibco, Co.; USA) at a final concentration of 9 %
(V/V)], along with the ~p~rative control Vero cell prior to cloning, to form monosheets of the individual cells. As culture .......
~- -. . "
. CA 02240843 1998-06-17 containers, two tissue culture test tubes were used per each cell strain. After the formation of the monolayer, the media in the individual containers were exchanged to a fresh MEM with no addition of serum, for additional culturing overnight. Then, the virus suspension (0.2 ml) of AU64 strain was inoculated into the cells in the individual containers and was then left to stand at 37 ~ for 60 minutes, to adsorb the virus onto the cells, followed by discarding the inoculation solution. Subsequently, an MEM
[supplemented with trypsin type IX (manufactured by Sigma, Co., - 10 USA) at a final concentration of 0.5 ~ g/ml] as a virus proliferation medium was added at 1 ml/container, for roller tube culture of the virus at 37 ~ for 7 days. After the termination of culturing, the culture fluid was collected andstoredas a virus suspension at -80 ~. By repeating the same virus culturing by using each of these virus suspensions, the virus was passaged over 7 generations. By the following fluorescent antibody technique (FA) and enzyme antibody technique (EIA), the infectious titer (FFU) of the virus suspension of each generation was assayed.
Into each cloned cell strain and the com~rative control cell after culturing in a chamber slide (manufactured by Nunc, Co., U~A) in the same manner as described above, were added the virus suspensions serially diluted 10-fold of each generation, for culturing at 37 ~ for 2 days, to fix the individual cells and subsequently count the FFU by indirect FA and EIA. The cells were fixedby gentlyrinsing thecellssequentiallyinPBSanddeionized .
water and immersing then the cells in acetone with addition of meth~nol at a final concentration of 10 % (V/V) at ambient temperature for 5 minutes.
The FA was performed, by using anti-human rotavirus guinea pig hyperimmune serum for the primary reaction and FITC-labeled goat IgG (manufactured by Cappel, Co., U~A) for the secondary reaction.
Meanwhile, EIA was practiced by individually using guinea pig hyperimmune serum against the rotavirus of group A for the - . 10 primary reaction and peroxidase-labeled anti-guinea pig IgG goat serum ~manufactured by Cappel, Co., U~A) for the s~.on~y reaction; and the chromogenic reaction was carried out by using a substrate solution [4-chloro-1-naphthol (manufactured by Bio-Rad, Co., U5A) at a final concentration of 1 mg/ml, 20 % (V/V) methanol and Tris-HCl buffer containing 35 % (V/V) aqueous hydrogen peroxide at a 1/1000 volume].
Theresultsof theFFU countingas describeda~oveareshown in Table 2. The adaptation of the rotavirus to each cloned cell strain highly permissive, as recovered in Example 1, was promoted in a smooth fashion, and a passaged virus with an infected virus volume inlog (in unit FFU/ml) of 6.5 or more was storedas a cloned Vero cell- adapted virus strain at -80 ~.
Table 2 Number of Cloned cell strain Comparative virus control passage Vero CL-9 Vero CL-16 Vero CL81-7 Vero CCL81 1 5.3 4.8 5.1 2.7 2 5.8 5.3 5.5 2.7 3 6.0 5.4 5.7 2.8 4 6.7 6.0 6.2 6.9 6.1 6.4 6 7.2 6.2 6.6 7 7.3 6.5 6.8 Numerical figure : in log (FFU/ml).
- : not practiced.
Vero CCL 81 : Vero cell (ATCC CCL 81) prior to cloning.
F.~r~le 3 (1) Isolation of novel human rotavirus strain AU64n AGMK (African Green Monkey Kidney) cells were cultured in a culture test tube in the same manner as in Example 1, to form a monosheet, and thereafter, the medium was exchanged to a fresh non-serum-added MEM the day pr~i ng the inoculation of a virus isolation material described below.
On the other hand, a virus isolation material was prepared as follows. Diarrhea feces (0.1 g) from an infant infected with rotavirus was suspended in 0.9 ml of MEM, and into the resulting suspension was added and mixed the aforementioned trypsin type IX to a final concentration of 10 ~ g/ml, which was then kept warm at 37 ~ for 20 minutes. Subsequently, the suspension was centrifuged with a micro high-speed centrifuge at 10,000 rpm for 30 seconds, and the resulting supernatant was collected and dilutedlO-foldwithMEM, and then, the dilution waspassed through a filter ofa diameter of 0.22 ~ m for disinfection. The filtrate was diluted serially 10-fold in a virus proliferation medium (MEM
supplemented with trypsin type IX at a final concentration of 0.5 ~ g/ml), and the resulting solution was defined as a virus isolation material.
After the medium for the AGMK cells was discarded, 1 ml each of the virus isolation material described above was added - 10 to the cells in each test tube. The tube was kept warm at 37 ~
for one hour, to adsorb the virus in the isolation material onto the cells, and subsequently, the inoculation solution was discarded. The cells were rinsed once in the virus proli~eration medium (1 ml/tube). After discarding the rinse solution, then, a fresh virus proliferation medium (1 ml/tube) was added to the individual cells, for roller tube culture. By freezing and thawing the cells with CPE observed during the culture, together with the culture fluid, a sample was prepared. By ELI~A (Example 1), the rotavirus antigen was assayed in each sample, and then, a samplepositive with theantigen was recovered. Thesupernatant of the sample centrifuged at a low speed was subjected as a primary virus to the following passage.
(2) Passage of novel human rotavirus strain Trypsin type IX was added and mixed into the primary virus, for incubation at 37 &~ for 90 minutes (referred to as "virus activation" hereinbelow), and the resulting solution was diluted 10-fold with MEM, and in the same manner described above in (1), the dilution was inoculated and cultured in fresh cells described below, for continuous passaging of the virus. Consequently, a human rotavirus strain comprising 5 passages in AGMK cells, subsequent 5 passages in Vero cells (ATCC CCL 81) and additional 2 passages in Vero CL-9 cells (FERM BP-6028) (passage history is represented according to a principle, for example "AGMK/5, Vero CCL81/5, Vero CL-9/2" below).
The serotype and genotype of the ~reshly isolated human rotavirus strain were analyzed according to the analysis method of serotype and virus genome RNA by means of electrophoresis pattern, as described in the report by the present inventors (Microbiology and Immunology, 38(4), p.317 - 320, 1994). It was elucidated that the serotype and genotype were GlPlB[4]. Because the serotype and genotype are the same as those of the AU64 strain, according to the classification shown in Table 1, the novel human rotavirus strain was designated as AU64n.
(3) Adaptation of the AU64n strain virus to "AGMK/5, CCL81/5 and Vero CL-9/2"
Theadaptationwas carriedoutbyplaquecloningas follows.
Vero CL-9 cells were cultured in a 6-well Falcon plate (manufactured by Becton Dickinson, Co., USA) in a CO2in~lh~tor~
until a monolayer of cells was formed. Then, the medium was replaced with a non-serum-added MEM, for additional culturing overnight. Subsequently, the AU64n strain virus activated with trypsin as described above was diluted 10-fold with the virus proliferation medium, and the resulting solution was inoculated at 1 ml/well into the cells. After adsorbing the virus onto the cells while keeping warm the mixture at 37 ~ for one hour, the inoculation solution was discarded. Then, an agar medium [199 - 10 medium (manu~actured by FMOBIO PRODUCTS, Co.) supplemented with agarose ME at a ~inal concentration o~ 0.7 % ~w/v) and 0.5 ~
g/ml trypsin type IX] was overlaid at 2 ml/well, and a~ter the solidification of the agar, the plate was upside down, to continue the culture. Onday4 and7aftervirusinoculation,individually, the agar medium was repeatedly overlaid to continue the culture, and on day 11, additionally, agar medium supplemented with a~;tion of Neutral Red (manufactured by Wako Pure Chemical Industries, Co.) at a final conç~ntration of 0.003 (W/V) was overlaid, for continuing the culture to form a plaque by cell st~ining. On day 12, an independently separated plaque with a larger diameter was collected (cloned). The plaque was suspended in MEM, and by the same method as for the virus passage described in (2), the virus was once amplified in Vero CL-9 cells, for subsequent another plaque cloning. After repeating the proceduresofcloningandvirus amplification three timesin total, additionally, passaging over two generations were done in Vero CL-9 cells, followed by fourth plaque cloning and amplification, and the resulting AU64n strain virus was further passaged over one generation in Vero CL-9 cells, to prepare an original seed ofthehuman rotavirusAU64nstrain (thep~cc~gehistoryis"AGMK/5, Vero CCL81/5, Vero CL-9/12"). The infectious titer on each passage level was assayed in log (FFU/ml) in the same manner as described in Example 2. The titers were as follows in the passaging order.
- 10 2.5, 3.7, 4.6, 5.4, 5.8 (passaged over 5 generations in AGMK);
2.8, 3.5, 3.6, 4.0, 4.4 (passaged over S generations in Vero CCL81);
ROTAVIRUS INFECTIONS, AND A METHOD FOR PRODUCING THE ANTIGEN
Technical Field The present invention relates to rotavirus antigens of which themassproductionvia cell culturearedifficult,avaccine against rotavirus infections and a diagnostic agent of the diseases and methods for producing the same. More specifically, the present invention relates to a vaccine and a diagnostic agent useful for the prophylaxis and diagnosis of rotavirus infections, and rotavirus antigens as the effective ingredient thereof. The present invention makes contributions to the prophylaxis and ~i~gno~is of rotavirus infections in humans, in particular.
Background Art Rotavirus is a pathogenic microorganism causing diarrhea inhumans,monkeys,dogs,cats,horses, cows,pigs,sheep,rabbits, rats, chickens, turkeys and the like, and is widely distributed all around the world. Rotavirus infections in humans in particular have been drawing attention, as vomiting and diarrhea in babies, winter-tenm diarrhea in babies, diarrhea with white feces, kid pseudo-cholera and the like. The prophylaxis and diagnosis thereof have been expected strongly at a worldwide scale.
What will be described below has been known concerning rotavirus.
~o~hol ogy and gename structure According to the6-th reportby theInternationalCommittee of Taxon~myofViruses, thevirusbelongs to the family Reoviridae, and is in an exact icosahedron of a diameter of about 70 nm, comprising a double capsid structure of inner and outer capsids (three layers in total, including the int~rm~i~te layer) with no envelop, and has a core of a diameter of about 50 nm at the center of the inner capsid. Inside the core is present a genome, comprising alin~r double-stranded RNA with 11 segments, and the sizes of these genome segments are within a range of 0.6 to 3.3 kbp ("~irus Taxonomy: Sixth Report of the International C~m--mittee of T;~ n~lmy of Viruses", Archives of Virology, Supplement 10, pp.219 - 222, 1995).
Genotype and serotype From the standpoint of developing a vaccine and a diagnostic agent therefor, attention has been focused particularly on the fourth genome segment and the ninth genome segment (corresponding to the seventh or eighth genome segment in some strain), among the 11 genome segments described above.
Rotavirus strains isolated worldwide have been classified into six groups (serogroups) from A to F and each group is divided into various serotypes; for convenience, additionally, rotavirus strains are broadly grouped depending on the genotypes. These isolated strains have a variety of both antigenicities and genotypes ("Fields Virology", 3rd ed., vol.l2, pp.l625 - 1629, edited by B. N. Fields et al., Lippincott-Raven Publishers, 1996, 5 USA). The following description is about what is described ;mm~t~i~tely above.
The fourth genome segment encodes the structure protein VP4 exposed in a spike form on the surface o~ the virus particle, and it is reported or assumed that VP4 may functionally be involved 10 in blood cell agglu~i ni n.C, neutralizing antigens, the infectivity promoted by protease, pathogenicity, membrane fusion, adsorption to cells, and so on. Based on the arnino acid sequence of the VP4 and the homology with the RNA or cDNA of the gene, rotavirus stains are currently classified into 20 genotypes (referred to as "P
15 genotype" hereinbelow); and based on the neutr~li 7i ~tg test, rotavirus strains are also classified into 10 or 14 serotypes (referred to as "Serotype P" hereinbelow).
The ninth genome segment (seventh or eighth genome segment in some strain) encodes the outer capsidVP7 o~ the virus particle, 20 and it is reported or assumed that the VP7 may possibly function to retain the epitope of neutralizing antigen and two hydrophobic regions. Based on the neutralizing test o~ the VP7, rotavirus strains are classified into 14 serotypes (referred to as "serotype G" hereinbelow).
25 Classi~ication o~ rotavi~us strains Among a great number of various isolated strains reported previously ("Fields Virology", 3rd ed., vol.2, p.l627), a typical human rotavirus strain of the group A and the following strains isolated and reported by the present inventors, namely AU-l 5 (Journal of Clinical Microbiology, 25, 1159 - 1164, 1987), AU32 (MicrobiologyandImmunology, 34, 77-82, 1990) andAU64 (Archives of Virology, 19, 67 - 81, 1991), are broadly classified as follows in Table 1.
Table 1 Name of strain Serotypes G and P tgenotype]
Wa GlPlA[8]
DS-l G2PlB[4]
P G3PlA[8]
A~-1 G3P3 [9]
Hochi G4P~A[8]
ST3 G4P2A[6]
AU32 G9PlAt8]
AU64 GlPlB[4]
Detection ~requency of~ serotype According to about20 research reports worldwide about the detection frequency of the serotype G of rotavirus, type Gl is main, occupying about 60 to 85 % in Japan, European countries, Australia and Central Africa and the like, while the remaining partisprimarilyoccupiedby types G2 andG3. InIndia, Thailand, Bangl~ h, Mexico and the like, alternatively, Gl, G2 G3 and G4 are detected in a sporadic fashion, and the ratio of them in total ranges at about 20 to 80 %, and the sporadic occurrence of other types except these types is also observed prominently.
virus culture Because rotavirus isolated from monkeys and cattle is generally grown in a culture cell in a relatively ready manner, the culturing or passages thereof is not essentially hard.
However, so-called abortive infection occurs during the passage of human rotavirus in cell culture, characteristically involving the generation of a virus antigen impossible of serial passages for obtaining the infectious virus particle, and therefore, the virus p~C~geis very hard. Hence, aprocedure has been designed, comprising preparing a reassortantbetween a human rotavirus with a low growth potency and a monkey- or cow-derived rotavirus with a high growth potency, to improve the growth potency of human rotavirus, or comprising inoculating a human rotavirus pr~l imin~rily treated with trypsin into a monkey-derived cell strain MA104 (ECACC No. 85102918) and AGMK (African Green Monkey Kidney) cells, and thereafter injecting the rotavirus to the roller tube culture using a maintenance medium supplemented and mixed with trypsin. Currently, almost all human rotaviruses of the group A can directly be cultured or isolated in laboratories.
However, even through the above roller tube culture, a virus antigen at an amount required for the production of vaccine or diagnostic agent cannot be recovered. Still currently, the culturing or passaging of rotaviruses except the viruses of the group A is at a very difficult stage.
Host of virus culture For the culturing of permissive cells permitting the proliferation of rotavirus, the following individual cell strains have been known, other than the MA104 and GMK cells; individual cells of FBK (fetal bovine kidney), CMK (cercopithecus monkey kidney), MK (crab-eating macaque kidney), etc.; individual cell 10 strains of monkey-derived CV-1, FRh L2, BSC-l, and Vero cell and dog-derived MDCK, human intestinal epidermis-derived CaC0-2, etc.
(WO 92/01784, Japanese Patent Laid-open No. 06-328107, the "Fields Virology", 3rd ed., vol.2, pp.1647 - 1648, pp. 1661 - 1162). For the mass production of rotavirus antigen for the purpose of 15 pro~ ~i n~ a vaccine, furthermore, cell strains for use in pro~ ;ng other virus vaccines, such as Vero, DBS-FLC-1, DBS-FLC-2, DBS-FRh L2, ESK-4, HEL, IMR-90, MRC-5, MRC-9, WI-38, and WRL68, can be utilized ~"ATCC Microbes & Cells at Work/', 2nd ed., p.144, A~Lerican Type Culture Collection 1991, USA).
Vaccine Various vaccines against human rotavirus infections have been attempted and developed since around 1985. The main stream lies in the development of a live vaccine by so-called Jennerian 25 approach, wherein a non-human-derived attenuated vaccine with a similar antigenicity is used as vaccine in place, like small pox vaccine; for example, it has been known clinical trials of live vaccines by using a cow- or monkey-derived attenuated v~c~in~ or an attenuated reassortant between two virus strains each derived from both humans and cow or from both humans and monkeys (WO
92/01784; EPO 130906; J~p~n~e Patent Laid-open No. 06-328107;
"Modern Vaccinology", pp. 213 - 229, edited by E. Kurstak, Plenum Medical Book Company 1994, USA; "Vaccines", 2nd ed., pp. 809 -822, edited by S. A. Plotolokin and E. A. Mortimer, W. B. Saundors ~ 10 Company 1994, USA; "The Jordan Report - Accelerated Development of va~in~s 1996~, p. 46 and p.68, National Institute of Health issued, USA). As the data of the clinical trials of these live vaccines or the oral dosing thereofhas been~ ml~l~ted, however, it has been remarked increasingly that the prophylactic effect is notsufficient. Currently, therefore,an attempthasbeenmade for the production of a vaccine based on a different idea from the idea of the Jennerian approach.
Diagnostic agent Antigens are mainly detected withpolyclonal or monoclonal antibodies, and kits for EIA (enzyme immllno~Say), ELISA
(enzyme-linked immunosorbent assay), latex agglutination and passive hemagglutination, for example, are now c~mm~rcially av~ hle. Diagnostic methods at gene levels by means of PAGE-SS
(polyacrylamide gel electrophoresis with silver stain), PCR
(polymerase chain reaction) and the like are now developed ("Principles andPracticeofInfectiousDiseases",4thed.,vol.2, pp. 1450 - 1451, edited by G. L. ~n~l 1 et al., Churchill Livingstone 1995, U5A). Because no diagnostic agent by means of virus antigens for antibody detection has been distributed yet, data relating to the temporal variation of various antibodies against rotavirus antigens in patients is still likely to be insufficient, although such data is extremely useful for the elucidation of rotavirus infections and the count~rm~cure thereof including prophylaxis and therapeutic treatment.
Insuch circumstance~onc~rninghuman rotavirusashasbeen described above, the present invention has been attained. It is an object of the present invention to overcome the current stage such thatthemassproductionofrotavirus antigenviacell culture is very difficult, and provide a method ~or producing a rotavirus antigen at a large scale, the antigen being required for producing a v~i n~ against rotavirus infections, and a diagnostic agent of the diseases.
It is the other object of the present invention to provide the antigen recovered by the method described above, a vaccine against rotavirus infections and a diagnostic agent of the diseases, which are to be produced by using the antigen.
Disclosure of the Invention So as to overcome the problems, the present application provides the following inventions.
More specifically, a first aspect of the present invention is a method for producing a rotavirus antigen, comprising cloning a cell highly permitting the proliferation of rotavirus from a cell culture; preparing a cloned cell adapted-rotavirus strain by passaging a rotavirus in the resulting cloned cell strain and adapting the rotavirus to the cloned cell strain; culturing as a seedvirus theadaptedrotavirusstrain ora reassortantprepared - 10 ~y using the adapted rotavirus strain as a parent strain; and isolating and purifying the rotavirus antigen from the culture medium of the seed virus.
In a preferable embodiment of the first aspect of the present invention, the culture cell is Vero cell (ATCC CCL 81).
In another pre~erable embodiment of the first aspect of the present invention, the cloned cell strain is Vero CL-9 (FERM
BP-6028).
As a still other preferable embodiment of the first aspect of the presentinvention, the rotavirus is human rotavirus strain AU32n and/or AU64n.
A second aspect of the present invention is the rotavirus antigen recovered by the aforementioned method.
A third aspect of the present invention is an inactivated antigen prepared by further inactivating the rotavirus antigen of the second aspectof the presentinvention with an inactivator.
A fourth aspect of the present invention is a vaccine against rotavirus infections, the v~; n~ containing the rotavirus antigen of the second aspect of the present invention or the inactivated antigen of the third aspect of the present invention at an amount for causing an immune response.
A fifth aspect of the present invention is a c~mh; n~
multivalent vaccine for rotavirus infections, containing two or moreantigensatan amountrequiredforanimmlln~response~wherein the antigens are the rotavirus antigen of the second aspect or the inactivated antigen of the third aspect and the serotypes or genotypes thereof are different from each other.
A sixth aspect of the present invention is a diagnostic agent, containing the rotavirus antigen of the second aspect or the inactivated antigen of the third aspect at an amount required for an antigen-antibody response.
A seventh aspect of the present invention is a cloned cell strain Vero Cl-9 (FERM BP-6028).
An eighth aspect of the present invention is a cloned cell adapted-human rotavirus strain A~32n.
A ninth aspect of the present invention is a cloned cell adapted-human rotavirus strain AU64n.
In this application, the term "cloned cell strain" means a culture cell of a clone singly composed of theprogeny ofasingle cell (species).
The term "adaptation" means the promotion of the mutation or selection of virus proliferation potency to fit the proliferation potency to the purpose, so that a virus mass production mightbepossibleunder constant conditions of the cell type and temperature for virus culture. For example, a virus adapted to a certain cell can proliferate well in the cell and a virus adapted to low temperature can proliferate well at the low t~r~rature~
~ le term "permissive" means the "permissive" property of a cell to permits virus proliferation. For example, the tenm "rotavirus permissive cell" means that rotavirus can proliferate or can be cultured in the cell.
~ le term "cloned cell-adapted virus strain" means a virus which is adapted to a cloned cell strain, by serial passages of the virus in the said cloned cell strain.
Other terms are apparently shown in the following description of the best mode for carrying out the invention.
Best Mode ~or Carrying out the Invention Each invention in this application can be practiced, by carrying out the following ~irst to ~ourth processes.
First process: cloning a cell highly permitting the proliferation of rotavirus, namely highly permissive cell, frQm a cell culture.
Second process: preparing a cloned cell adapted-rotavirus strain which is adapted to the cloned cell strain recovered at the preceding process, under serial passages of the virus in the cloned cell strain, namely an adapted rotavirus strain ~p~hl e of extremely actively or highly proliferating in the cloned cell strain. If n~, a reassortantis preparedby using the adapted rotavirus strain as a parent strain. The rotavirus to be used at the first process is not necessarily the same as the rotavirus cultured at the second process.
Third process: mass producing rotavirus antigens, namely complete rotavirus particle, incomplete rotavirus particle, - -- 10 antigenic protein, genome, gene and the like, by culturing as a seed virus the adapted strain or the reassortant recovered at the preceding process.
Fourth process: preparing and producing vaccines, diagnostic agents, and reagents and the like, by purifying, processing or modi~ying the complete rotavirus particle, incomplete rotavirus particle, antigenic protein, genome, gene and the like, as recovered at the pr~ ng process.
The processes are now described below sequentially in the order.
Culture cell to be used at the ~irst process As the subjective culture cell for cloning a cell highly permitting the proliferation of rotavirus, use is made of various cells or cell strains as previously described in the section of the "Hostforvirus culture"in theBackgroundArt. Foruse, then, a culture cell in which the absence of adversely affecting cont~min~ted factors or cancer genes is concluded, for ~m~le Vero cell (ATCC CCL 81), is preferably used.
l~otavirus for use at second process As the rotavirus tobepassagedin and adapted to the cloned cell strain reGovered at the aforementioned process, use is made ofisolatedstrainsdescribedin thereference ("Fields Virology", ~ 3rd ed., vol.2, p.l627, Archives of Virology, 19, 67 - 81, 1991, - 10 etc.) or appropriate rotavirus strains. Particularly, a strain to be passaged during cell culture with much di~ficulty or a virus strain promising for the increase of the production o~ antigens is pre~erable. For ~7~rle, known strains o~AU-l, AU32 andAU64, and novel human rotavirus strains with an appropriate passage history as a virus strain for vaccine production, such as AU32n and AU64n, which are to be provided in accordance with the present invention, are preferable.
Cell culture medi7m, and m~7;77m ~or virus growth Known and c~mm~rcially av~ hle media, for example 199 medium,MEM (Eagle's~i ni mllm Essential Medium),BME (Eagle'sBasal Medium), Hanks solution, andDulbecco's phosphatebufferedsaline (PBS), may be used. The compositions and preparative methods thereof are described in detail in general texts relating to virus experiments, cell culture and tissue culture (for example, "Cells & Tissue Culture; T~horatory Procedures", 2 volumes in total, editedby A.Doyle etal., JohnWiley &Sons 1993,USA) and catalogs of c~mm~rcially available products. Such media and salt solutions may be supplemented and modified with auxiliary agents or additives. As the additives, use may be made of routine subst~n~s;itisselectedfrom forexample~mm~rciallyav~ hle human serum, fetal calf serum, antibiotics, sodium hydrogen carbonate,sodiumchloride, non-essential aminoacids and thellke, for use at an appropriate amount. For example, the final concentrations of the a~itives to be added and mixed with one liter of a culture medium are as follows; sera at about 3 to 25 %
(V/V);sodiumhydrogen carbonate ataboutl to 6g;sodiumchloride at about 0.1 to 0.25 mole; and non-essential amino acids at standard amounts as described in the product catalogs. It has been known that protease or trypsin in particular is preferably added and mixed into rotavirus proliferation media. Herein, the final trypsin cQ~c~ntration in the media for rotavirus growth is about 0.1 to 10 ~ g/ml.
20 Cell culture and cell ~-70n;n~
The passage of a cell strain generally comprises preparing a cell suspension ataboutlX105- 4X105cells/ml ina cell culture medium, and passaging the suspension of a volume about 1/10 to 1/5-fold the volume of a culture container, for example about 10 25 - 20 ml in a 100-ml container and culturing then the cell at about 37 ~C. So as to peel off cells having formed a m~nocheet on the bottom of the container from the area of the culture container and then disperse the cells, generally, use is made of a trypsin solution of about 0.25 % (W/V) as the final co~ntration~ which is preliminarily prepared in PBS fram which both Ca and Mg ions are eliminated.
According to the routine method ("Cells & Tissue Culture;
LaboratoryProcedures",vol.1,pp.4B:3,supra.),cellsarecloned Cell cloning may satisfactorily be effected, for ~mple~ by a method (colony forming method) for preparing a clone singly composed of the progeny of a single cell, comprising peeling off a monosheet of cultured cells in the trypsin solution and dispersing the sheet in the cell culture medium to prepare a suspension of a free cell (aboutl to 5 cells/ml), theninoculating the suspension into culture cont~i n~S, for example petri dish or microtest plate, for culturing. Recovered colonies are independently cultured to increase the cell number, whereby a cloned cell or a cloned cell strain can be recovered.
20 Virus c1lltu:ring and passage and adaptation The temperature for virus culture in a hostof cell culture is generally about 20 to 37 ~C, and the culture duration is about 2 to 16 days. Stationary culture or roller tube culture may satisfactorily be used. The supernatant of the culture fluid after culturingissubjectedtoviruspassageas avirussuspension .~ .. _- - . . .
.~.
Virus passaging is effected by sequentially inoculating virus suspensions in fresh culture cells to proliferate the virus. By repeating the virus passaging in a specific cell about 2 to 50 times, preferably about 3 to 20 times, a specific cell-adapted 5 virus strain very highly proliferating in the cell can be recovered By preparing a reassortant between the adapted virus strain as the parent strain and another virus strain, the high proliferation potency of the adapted virus can be transferred into a different virus strain. E~y mi7ci ng together a rotavirus strain inactivated - - 10 with the irradiation of ultraviolet ray (W) and the adapted virus strain (parent strain) and culturing themixture, thereby in~ ~ing the reassortment of the genome segments of the viruses of both the strains, and eliminating the parent strain virus with an anti-parent strain neutralizing antibody, a r~m~i n i ng infectious 15 virus can be recovered as a reassortant.
Selection o~ highly p~m; c~ ;ve ~on,~l cell strain ~or rotavirus By inocula'cing and culturing rotavirus in each cloned cell, the numbers of infectious viruses and virus particles or the level 20 of virus antigen, which are generated through the virus proliferation, is det~ined. In this case, it is i-m$~ortant to determine the extent of the proliferation due to the difference in ~I (multiplicity of infection), namely so-called virus production level, high or low, depending on the difference in virus 25 inoculation level, by a method described below. By screening a cloned cell in which the virus can highly proliferate by using such measured values as markers, a highly permissive cloned cell strain can be yielded. The measurement is done by plaque forming method (counting PFU (plaque forming unit)), focus forming method (counting FFU (focus forming unit)), ELISA, IME(immune electron microscopy) and the like. Herein, FFU is counted by fluorescent antibody technique comprising staining an infectious cell region formed due to the infection and proliferation of the virus with a fluorescent dye FITC (fluorescein isothiocyanate)-labeled antibody, by EIA (enzyme immunoassay) and the like.
Mass production and preparation ol~ virus and antigen By using a cell culture o~ a highly permissive cloned cell strain as a host and culturing a virus strain adapted to the cell strain, the virus and an antigen are produced at a large scale.
More specifically, after the termination of culturing, a supernatant of a virus culture fluid after centrifugation at a low speed (for example, a supernatant of a suspension of a virus infected cell after freezing and thawing in dry ice and an organic solvent) is collected, to prepare a complete virus particle and the antigen. Such preparation may be used as the virus suspension as it is. The suspension is possibly disinfected by membrane filtration, or antibiotics may satisfactorily be added to the suspension. The virus antigen in the suspension and the like may be concentrated and purified by membrane concentration, density gradient ultra-centrifugation, ultra-centrifugation on a sucrose cushion. The virus suspension is overlaid on a sucrose solution as a cushion, for example, for subsequent ultra-centrifugation, to precipitate the virus antigen on the bottom of a centrifuge 5 tube, and the precipitate is again susp~n~ to prepare a purified virus antigen.
Preparation of ~ v~ ; ne b2l1k solution A vaccine bulk solution can be prepared by using the virus - 10 suspension or purified virus antigen. As the antigen for vaccine, furth~rTn~e, use may be made of complete virus particles, incomplete virus particles, protein of the virion structure for r~le VP4 and VP7, neutralizing reaction epitope region, and modified structural protein after translation and the like in the 15 virus suspension, andprotein of non-virion structure andmodified protein after translation, and protective antigens against infection and the like. Such antigens for vaccine can be iTTm~hilized with inactivating agents, so that the steric structure can be st~hilized As the inactivating agent, for example, use 20 maybemadeof formalin, phenol, glutaraldehyde, B-propiolactone and the like, which are added into a vaccine bulk solution prior to or after the preparation of the solution. If used, fo~n~li n is added at an amount of about 0.005 to 0.5 % (V/V), and the inactivation temperature is about 2 to 38 ~C and the inactivation 25 time is about 5 to 180 days. When the antigenicity is deteriorated through such inactivation, however, an instrumental measure is required formodi~ying theinactivation conditions, including for example the reduction of the amount o~ the inactivator, the a~;tion of neutral amino acid or basic amino acid, and the lowering of the inactivation temperature. The ~ree formaldehyde r~m~;ni ng at the inactivationprocess canbe neutralizedby adding an equal amount of sodium hydrogen sulfite or can be ~limin~ted during dialysis. The preparation thus produced is subjected to the following process as a vaccine bulk solution.
Preparation o~ vaccine The vaccine bulk solution is diluted for example in a culture medium BME, to adjust the antigen level in the vaccine to the level required for antibody generation.
Then, a stabilizer for enhancing the heat resistance of the vaccine or an adjuvant as an a~ ry agent for e~h~n~ing the immunogenicity, may be added and mixedinto the bulk solution.
For ~m~le~ use may be made of sugars and amino acids as st~hilizers; and mineral oil, vegetable oil, alum, aluminum phosphate, bentonite, silica, muramyl dipeptide derivatives, thymosin, interleukin and the like as auxiliary agents.
For the purpose of the induction of mucosal immllnity or local immllnity~ the virus antigen in the vaccine bulk solution may be treated or modified. For the induction, a technique relating toDDS (drug delivery system) using for exampleliposome, emulsion, microcapsule, microsphere, polylactic acid, and polyglycolic acid is applicable.
Then, the v~c~i~ solution is divided into a vial of an appropriate volume, for example about 1 - 20 ml, followed by stopping and sealing, and the resulting vaccine solution is subjected to use. The vaccine is not only at a liquid state but is also subjected to use as a dry formulation by freeze-drying the solution after division. For the purpose of oral administration, the vaccine solution is possibly processed into for example syrups or candies.
$o as to guarantee the quality prior to use, namely during the production processes thereof and at the division stage of the solution in small portions, the prepared v~c~;n~ form~ tion is testedas to thesafetyandefficacy, toverify theappropriateness of the solution as vaccine. Such testing can be practiced following the standard for a formulation similar to the rotavirus vaccine of the present invention, for example, the Regulation "Inactivated Acute Polymyelitis Vaccine Standard" defined in "Biological Formulation St~n~rd" according to the Ph~rm~utical Law (Law No.145, 1960) and Notification No.315, 1960 of theMinistry ofHealthandWelfareandNotificationNo.337, Revision, 1961 of the Ministry of Health and Welfare; both the Regulations "Japanese B Encephalitis Vaccine" and "Dry Japanese B Encephalitis Vaccine" as defined in the "Biological Formulation St~n~rd" according to the aforementioned Pharmaceutical Law and Notification No.217, 1993 of the Ministry of Health and Welfare;
or the Regulation "Dry TissueCulture Inactivated Type AHepatitis Vaccine" defined in the "Biological Formulation Standard" according to the aforementioned Ph~rm~c~lltical Law and Notification No.332, 1994 of the Ministry of Health and Welfare;
and the like.
Dosage of V~r~i n~
Vaccine inoculation is practiced, by inoculating the - 10 vaccine subcutaneously for example at a dose of about 0.25 to 0.5 ml; by orally administering one dose of about 1.0 ml; or by injecting about 0.05 ml of the v~i n~ into oral cavity.
Furthermore,suchinoculationispreferablypracticedone tothree times at an inter~al of about 2 to 4 weeks. However, the vaccine dosage is not limited to the ~rles described above.
Preparation of~ n;~nostic agerlt In the same fashion as described above, a virus suspension or a purified antigen or the like is prepared, which is then provided as a diagnostic antigen (for example, antigens for precipitation reaction, agglutination reaction, neutralizing reaction, fluorescent antibody technique, enzyme immunoassay, radioimmunoassay, etc.). By inoculating the diagnostic antigen or the vaccine bulk solution periton~lly/ subcutaneously, intra-muscularly in animals (for example, r~hhit, guinea pig, mouse, etc.), antibodies may be prepared from the sera of the animals. The antibodies are provided for antigen assay by the various diagnostic methods described above. The diagnostic antigens and antibodies in accordance with the present invention are diluted and adjusted to an amount required for inducing antigen-antibody reaction, prior to use. Fur~h~-re, the genome and its cDNA fragment of rotavirus in accordance with the present invention may be provided Eor ~le as probe reagents and identification reagents for gene diagnosis.
The present invention will now more specifically be described in further detail in the following examples, but the invention is not limited to the ~mrl es.
~le 1 15 (1) Cell cloning Vero cell (ATCC CCL 81) was cultured in a cell culture mediumMEMsupplementedwith FCS (manufacturedbyGibco, Co., USA) at a final concentration of 9 % (V/V) in a container with a culture area of 25 cm2 at 37 9C, to form a monosheet. The monosheet was 20 peeled off in 0.25 % (W/V) trypsin (trypsin 1: 250; manufactured byDifco, Co., USA~I solution from the area of the culture container, to disperse the cells to prepare the cells into a free single cell, and thereafter, the cells were collected with centrifugation at a low speed (1500 rpm, 5 minutes), to prepare a suspension of a 25 free single cell at 2 cells in cell number/ml in the culture medium.
The suspension was inoculated in 0.2 ml portions into each well of a 96-well microtest plate (Falcon Microtest III Plate;
manufactured by Becton Dickinson, Co., U5A) and was then cultured in a CO2 incubator at 37 ~ for 14 days, to form a colony singly composed of the progeny of the single cell on the surface of each well. The cells in each o~ the individual colonies were sequentiallypassagedthreetimesintoalarger cont~; n~,thereby increasing the number of the cells, where~y 40 in total of cell suspensions of individual Vero cell colonies were recovered.
(2) Screening of rotavirus permissive cloned cell strain Rotavirus in each of the cloned cells in total of 40 as recovered above in (1) was cultured and proliferated, to assay the rotavirus antigen in the culture supernatant by ELI~A, and then, a cloned cell strain with a far higher antigen titer than the titer of the Vero cell prior to cloning was screened as described below in a) to c).
a) Culturing of virus in each cloned cell Each cloned cell was assigned to eight wells in one cross row of the microtest plate (96 wells; 8 wells in cross direction X12 wells in lengthwise direction), and then, 40 in total of the cell suspensions of individual clones were independently inoculated at 0.2 ml/well, for incubation at 37 &~, to form a monosheet of each clone. Subsequently, the culture fluid in each well was exchanged to a fresh MEM with no addition of serum for further culturing overnight. Into the cells in each well was added 0.05 ml/well of rotavirus AU64 strain fluid activated with trypsin treatment in a medium for virus growth described below (provided that the final trypsin concentration was 20 ~ g/ml) at 37 ~ for 20 minutes, and then, the cells were left to stand at 37 ~ for 30 minutes, so that the cells could adsorb the virus.
Thereafter, an MEM with addition of trypsin to a final concentration of 0.5 ~ g/ml as a medium for virus growth was added at 0.2 ml/well, for culturing and proliferating the virus at37 ~
for 7 days. After the termination of the culture, the culture fluid in each well was subjected as a virus suspension (sample) to the assaying of virus antigen described below. As a c~mr~rative control, herein, the Vero cell prior to cloning was used.
b) Assay of virus antigen (primary screening) The antibody against rotavirus of group A (IgG purified from per-immunized serum in guinea pigs) was diluted in 50 mM
carbonate buffer, pH 9.6, to prepare an antibody solution at a concentration of 1.0 ~ g/ml. The antibody solution was added at 0 1 ml/well into a 96-well test plate for ELISA (ELISA-PLATE;
manufactured by Greiner, Co., Germany), which was then left to standat4 ~ overnight, toadsorb theantibody on thewellsurface.
After adsorption, each well was rinsed in a rinse solution [PBS
containing Tween 20 at a final concentration of 0.05 % (W/V)].
Meanwhile, each virus suspension described above was diluted 5-fold in an antigen dilution solution [Block A~e (manufactured by Snow Brand Milk Industry, Co. Ltd.) was diluted by 10-fold in deionized water], and the resulting prepared samples each were added in 0.1-ml portions into each well, for primary reaction at 25 ~ for 90 minutes. After rinsing the wells with the aforementioned rinse solution, then, peroxidase-labeled anti-rotavirus goat antibody (manufactured by Viro Stat Co., USA) was diluted 2,000-fold in the antigen dilution solution, and the - 10 resulting antibody solution was added at 0.1 ml/well, for se~on~ryreaction, againat25 ~, for90minutes. Subsequently, each well was rinsed in the rinse solution, followed by addition of a substrate solution [0.5M citrate - phosphate buffer, pH 5.0, contalning o-phenyl~n~i ~mi ne (manufactured by Wako Pure Chemical Industries, Co.) at a final concentration of 0.4 mg/ml and an aqueous 35 % (V/V) hydrogen peroxide solution (Wako Pure Chemical Industries, Co.)] at 0.1 ml/well, for chromogenic reaction at ambient temperature for 10 minutes, followed by further 0.05 ml/well addition of 4N sulfuric acid to terminate the reaction. After the t~rmin~tion of the reaction, the absorbance (OD) of each well was counted at a monochromatic ray at a wave length of 490 nm. As the results of the aforementioned primary screening, six samples with OD of 5-fold or more the OD
of the ~m~rative control were selected, and the correspon~i ng cloned cell strains were thensubjected to the followingsecondary screening.
c) Assay of virus antigen (secondary screening) In the same manner as described above in (1), cells of the six cloned strains were cultured in a microtest plate, and simultaneously, the AU64 strain was cultured and proliferated in the cells in each well. So as to observe the extent of growth, depending on the difference in MOI, additionally, the virus suspension was serially diluted 4-fold, and each dilution series - - 10 was assigned to one row in the lengthwise direction and two wells in the cross row. Additionally, the virus antigen was assayed by ELI~A, in the same manner as for the primary screening.
Consequently, three highly permissive cloned cell strains highly permitting the proliferation of rotavirus couldbe recovered, and these strains were individually designated as Vero CL-9 (FERM
BP-6028), Vero CL-16 and Vero CI-81-7.
F.~rr~le 2 Adaptation of rotavirus:
Individual cloned cell strains recovered in Example 1, namely Vero CL-9, Vero CL-16 and Vero CI-81-7, were cultured at 37 ~ in a cell culture medium MEM [supplemented with FCS
(manufactured by Gibco, Co.; USA) at a final concentration of 9 %
(V/V)], along with the ~p~rative control Vero cell prior to cloning, to form monosheets of the individual cells. As culture .......
~- -. . "
. CA 02240843 1998-06-17 containers, two tissue culture test tubes were used per each cell strain. After the formation of the monolayer, the media in the individual containers were exchanged to a fresh MEM with no addition of serum, for additional culturing overnight. Then, the virus suspension (0.2 ml) of AU64 strain was inoculated into the cells in the individual containers and was then left to stand at 37 ~ for 60 minutes, to adsorb the virus onto the cells, followed by discarding the inoculation solution. Subsequently, an MEM
[supplemented with trypsin type IX (manufactured by Sigma, Co., - 10 USA) at a final concentration of 0.5 ~ g/ml] as a virus proliferation medium was added at 1 ml/container, for roller tube culture of the virus at 37 ~ for 7 days. After the termination of culturing, the culture fluid was collected andstoredas a virus suspension at -80 ~. By repeating the same virus culturing by using each of these virus suspensions, the virus was passaged over 7 generations. By the following fluorescent antibody technique (FA) and enzyme antibody technique (EIA), the infectious titer (FFU) of the virus suspension of each generation was assayed.
Into each cloned cell strain and the com~rative control cell after culturing in a chamber slide (manufactured by Nunc, Co., U~A) in the same manner as described above, were added the virus suspensions serially diluted 10-fold of each generation, for culturing at 37 ~ for 2 days, to fix the individual cells and subsequently count the FFU by indirect FA and EIA. The cells were fixedby gentlyrinsing thecellssequentiallyinPBSanddeionized .
water and immersing then the cells in acetone with addition of meth~nol at a final concentration of 10 % (V/V) at ambient temperature for 5 minutes.
The FA was performed, by using anti-human rotavirus guinea pig hyperimmune serum for the primary reaction and FITC-labeled goat IgG (manufactured by Cappel, Co., U~A) for the secondary reaction.
Meanwhile, EIA was practiced by individually using guinea pig hyperimmune serum against the rotavirus of group A for the - . 10 primary reaction and peroxidase-labeled anti-guinea pig IgG goat serum ~manufactured by Cappel, Co., U~A) for the s~.on~y reaction; and the chromogenic reaction was carried out by using a substrate solution [4-chloro-1-naphthol (manufactured by Bio-Rad, Co., U5A) at a final concentration of 1 mg/ml, 20 % (V/V) methanol and Tris-HCl buffer containing 35 % (V/V) aqueous hydrogen peroxide at a 1/1000 volume].
Theresultsof theFFU countingas describeda~oveareshown in Table 2. The adaptation of the rotavirus to each cloned cell strain highly permissive, as recovered in Example 1, was promoted in a smooth fashion, and a passaged virus with an infected virus volume inlog (in unit FFU/ml) of 6.5 or more was storedas a cloned Vero cell- adapted virus strain at -80 ~.
Table 2 Number of Cloned cell strain Comparative virus control passage Vero CL-9 Vero CL-16 Vero CL81-7 Vero CCL81 1 5.3 4.8 5.1 2.7 2 5.8 5.3 5.5 2.7 3 6.0 5.4 5.7 2.8 4 6.7 6.0 6.2 6.9 6.1 6.4 6 7.2 6.2 6.6 7 7.3 6.5 6.8 Numerical figure : in log (FFU/ml).
- : not practiced.
Vero CCL 81 : Vero cell (ATCC CCL 81) prior to cloning.
F.~r~le 3 (1) Isolation of novel human rotavirus strain AU64n AGMK (African Green Monkey Kidney) cells were cultured in a culture test tube in the same manner as in Example 1, to form a monosheet, and thereafter, the medium was exchanged to a fresh non-serum-added MEM the day pr~i ng the inoculation of a virus isolation material described below.
On the other hand, a virus isolation material was prepared as follows. Diarrhea feces (0.1 g) from an infant infected with rotavirus was suspended in 0.9 ml of MEM, and into the resulting suspension was added and mixed the aforementioned trypsin type IX to a final concentration of 10 ~ g/ml, which was then kept warm at 37 ~ for 20 minutes. Subsequently, the suspension was centrifuged with a micro high-speed centrifuge at 10,000 rpm for 30 seconds, and the resulting supernatant was collected and dilutedlO-foldwithMEM, and then, the dilution waspassed through a filter ofa diameter of 0.22 ~ m for disinfection. The filtrate was diluted serially 10-fold in a virus proliferation medium (MEM
supplemented with trypsin type IX at a final concentration of 0.5 ~ g/ml), and the resulting solution was defined as a virus isolation material.
After the medium for the AGMK cells was discarded, 1 ml each of the virus isolation material described above was added - 10 to the cells in each test tube. The tube was kept warm at 37 ~
for one hour, to adsorb the virus in the isolation material onto the cells, and subsequently, the inoculation solution was discarded. The cells were rinsed once in the virus proli~eration medium (1 ml/tube). After discarding the rinse solution, then, a fresh virus proliferation medium (1 ml/tube) was added to the individual cells, for roller tube culture. By freezing and thawing the cells with CPE observed during the culture, together with the culture fluid, a sample was prepared. By ELI~A (Example 1), the rotavirus antigen was assayed in each sample, and then, a samplepositive with theantigen was recovered. Thesupernatant of the sample centrifuged at a low speed was subjected as a primary virus to the following passage.
(2) Passage of novel human rotavirus strain Trypsin type IX was added and mixed into the primary virus, for incubation at 37 &~ for 90 minutes (referred to as "virus activation" hereinbelow), and the resulting solution was diluted 10-fold with MEM, and in the same manner described above in (1), the dilution was inoculated and cultured in fresh cells described below, for continuous passaging of the virus. Consequently, a human rotavirus strain comprising 5 passages in AGMK cells, subsequent 5 passages in Vero cells (ATCC CCL 81) and additional 2 passages in Vero CL-9 cells (FERM BP-6028) (passage history is represented according to a principle, for example "AGMK/5, Vero CCL81/5, Vero CL-9/2" below).
The serotype and genotype of the ~reshly isolated human rotavirus strain were analyzed according to the analysis method of serotype and virus genome RNA by means of electrophoresis pattern, as described in the report by the present inventors (Microbiology and Immunology, 38(4), p.317 - 320, 1994). It was elucidated that the serotype and genotype were GlPlB[4]. Because the serotype and genotype are the same as those of the AU64 strain, according to the classification shown in Table 1, the novel human rotavirus strain was designated as AU64n.
(3) Adaptation of the AU64n strain virus to "AGMK/5, CCL81/5 and Vero CL-9/2"
Theadaptationwas carriedoutbyplaquecloningas follows.
Vero CL-9 cells were cultured in a 6-well Falcon plate (manufactured by Becton Dickinson, Co., USA) in a CO2in~lh~tor~
until a monolayer of cells was formed. Then, the medium was replaced with a non-serum-added MEM, for additional culturing overnight. Subsequently, the AU64n strain virus activated with trypsin as described above was diluted 10-fold with the virus proliferation medium, and the resulting solution was inoculated at 1 ml/well into the cells. After adsorbing the virus onto the cells while keeping warm the mixture at 37 ~ for one hour, the inoculation solution was discarded. Then, an agar medium [199 - 10 medium (manu~actured by FMOBIO PRODUCTS, Co.) supplemented with agarose ME at a ~inal concentration o~ 0.7 % ~w/v) and 0.5 ~
g/ml trypsin type IX] was overlaid at 2 ml/well, and a~ter the solidification of the agar, the plate was upside down, to continue the culture. Onday4 and7aftervirusinoculation,individually, the agar medium was repeatedly overlaid to continue the culture, and on day 11, additionally, agar medium supplemented with a~;tion of Neutral Red (manufactured by Wako Pure Chemical Industries, Co.) at a final conç~ntration of 0.003 (W/V) was overlaid, for continuing the culture to form a plaque by cell st~ining. On day 12, an independently separated plaque with a larger diameter was collected (cloned). The plaque was suspended in MEM, and by the same method as for the virus passage described in (2), the virus was once amplified in Vero CL-9 cells, for subsequent another plaque cloning. After repeating the proceduresofcloningandvirus amplification three timesin total, additionally, passaging over two generations were done in Vero CL-9 cells, followed by fourth plaque cloning and amplification, and the resulting AU64n strain virus was further passaged over one generation in Vero CL-9 cells, to prepare an original seed ofthehuman rotavirusAU64nstrain (thep~cc~gehistoryis"AGMK/5, Vero CCL81/5, Vero CL-9/12"). The infectious titer on each passage level was assayed in log (FFU/ml) in the same manner as described in Example 2. The titers were as follows in the passaging order.
- 10 2.5, 3.7, 4.6, 5.4, 5.8 (passaged over 5 generations in AGMK);
2.8, 3.5, 3.6, 4.0, 4.4 (passaged over S generations in Vero CCL81);
5.9, 6.4, 6.8, 7.0, 7.1, 7.1, 7.1, 7.2, 7.2, 7.2, 7.2, 7.2, (passaged over 12 generations in Vero CL-9).
F~ ~ le 4 (1) Mass culture of AU64n strain virus By using 10 roller bottles at once, the virus was cultured at a mass scale, and the procedure was repeated eight times in total. More specifically, the culture medium of the Vero CL-9 cells after roller bottle culture with Falcon roller bottles (manufactured by Becton Dickinson, Co., USA; product number of 3027) was exchanged to non-serum-added MEM, for additional culturing overnight, and then, the culture medium was discarded.
Into the cells in each bottle was inoculated the AU64n strain .
original seed recovered in Example 3, at 20 ml/bottle. Herein, the original seed was preliminarily activated with trypsin type IX. Subsequently, the cells were in~lh~ted under roller bottle culture at 37 ~ for one hour, to adsorb the virus onto the cells, and the inoculation solution was then discarded, followed by addition of a fresh virus proliferation culture medium at 80 ml/bottle, for roller bottle culture at 37 ~ for 2 days. After the terminationofculturing, the culturein eachbottlewas frozen and thawed to prepare a virus suspension, which was then pooled.
- 10 Thereafter, the virus suspension was centri~uged (3,000 rpm, 10 minutes), to recover the supernatant (800 ml per one culture), which was defined as a crudely purified virus suspension. The virus infectious titer (X106 FFU/ml) of each of the individually crudely purified virus suspensions, recovered through culture eight times in total, was assayed in the same manner as described in F.~c~mpl e 3, (3~. Consequently, the resulting titers in log (FFU/ml) were 4.9, 5.5, 10.0, 7.0, 7.5, 8.0, 4.2 and 4Ø
(2) Purification of AU64n strain virus By using the crudely purified virus suspensions, 4 lots were prepared in total, each lot of 1.2 liters. The virus of each lot was purified as follows. The crudely purified virus suspension ofeachlotwas centrifuged (10,000 rpmforlOminutes), and the resulting supernatant was collected, followed by further 25 ultracentrifugation (19,000 rpm, 6 hours), and the precipitate was suspended in 15 mM PBS, pH 7.5, to a final volume of 40 ml, which was a 30-fold ~nnc~ntrated solution. The concentrated solution was centrifuged (10,000 rpm, 10 minutes), and the supernatant was collected, which was then overlaid on a 30 (W/V) %
sucrose cushion, for ultracentrifugation (38,000 rpm, 3 hours).
After ultracentrifugation, the resulting precipitated fraction was again suspended in 15 mM PBS, pH 7.5, to recover the virus of a purified AU64n strain. The virus infectious titers of the 4 lots in total in re-suspension (6 ml/lot) were counted;
- 10 simultaneously, the protein was assayed by the phenol reagent method. Consequently, the virus infectious titer (XlO~PFU/ml) and [protein level (mg/ml)] were as follows; 3.8 [1.36] for #1;
4.8 [1.10] for #2; 3.3 [0.94] for ~3; and 1.3[1.57] for #4.
(3) Inactivation of AU64n strain virus From the individual lots (#1 through #4) were collected the re-suspension solutions (purified AU64n strain virus), each of 3 ml, and the pooled re-suspensions in total of 12 ml were diluted and adjusted with 15 mM PBS, pH 7.5 to a protein content of 100 ~ g/ml protein, followed by addition of formalin to a final concentration o~ 0.1 (V~V) %, and the resulting solution was left to stand at 4 &~ for 2 weeks. Then, the solution was dialyzed against 15 mM PBS, pH 7.5 at 5 ~ for 30 hours. So as to verify the appropriateness of theinactivated virus-containing solution after completion of the dialysis as an inactivated rotavaccine bulk solution, a variety of tests were carried out.
According to the Regulation "J~p~n~se B Encephalitis Vaccine"
definedin theBiological Fo~mll~tionStandard,morespecifically, protein content tests, coloring tests, sterile tests, inactivation tests and tests of the absence of abnormal toxicity were done, provided that the inactivation tests were conducted by using Vero CL-9 cells. Consequently, it was verified that the inactivated virus-containing solution was suitable as a vaccine bulk solution.
(4) Preparation of vaccine ~g~inst rotavirus infections The vaccine bulk solution was diluted with 15 mM PBS, pH
7.5, to adjust the protein content to 50 ~ g/ml, to prepare an inactivated AU64n v~c~in~. Meanwhile, 0.5 ml was collected from each of the non-inactivated 4 lots, and the pooled re-suspensions (purified AU64n strain virus) were adjusted to 50 ~ g/ml in the same manner as described above, and the resulting solution was defined as raw AU64n-cont~ining solution.
(5) Assaying of immunogenicity of inactivated AU64n vaccine The inactivated AU64n vaccine was inoculated twice at a dose of 10 ~ g protein/dose into ddy mice of age 4 - 5 weeks (7 animals) at an interval of 2 weeks, and on week 2, blood was drawn.
As ~om~rative controls, a raw AU64n-containing solution and 15 mM PBS, pH 7.5 both were used; the former was inoculated into 19 mice and the latter, into 10 mice, prior to blood collection. The neutralization antibody titer of each serum recovered for the AU64n strain was assayed by the 60 ~ plaque reduction method. The results are shown in Table 3, which verifies the ~c~llent immunogenicity of the resulting vaccine.
Table 3 Antigen for i~munization Neutralization antibody titer +
confidence limits Inactivated AU64n vaccine 2.20 + 0.23 Raw AU64n-containing solution 2.30 + O.12 15 mM PBS, pH 7.5 < 1.60 Neutralization antibody titer: geometric mean of antibody titers in common log of individual mice Confidence limits: significance level 5 %
F~ ~ le 4 (1) Mass culture of AU64n strain virus By using 10 roller bottles at once, the virus was cultured at a mass scale, and the procedure was repeated eight times in total. More specifically, the culture medium of the Vero CL-9 cells after roller bottle culture with Falcon roller bottles (manufactured by Becton Dickinson, Co., USA; product number of 3027) was exchanged to non-serum-added MEM, for additional culturing overnight, and then, the culture medium was discarded.
Into the cells in each bottle was inoculated the AU64n strain .
original seed recovered in Example 3, at 20 ml/bottle. Herein, the original seed was preliminarily activated with trypsin type IX. Subsequently, the cells were in~lh~ted under roller bottle culture at 37 ~ for one hour, to adsorb the virus onto the cells, and the inoculation solution was then discarded, followed by addition of a fresh virus proliferation culture medium at 80 ml/bottle, for roller bottle culture at 37 ~ for 2 days. After the terminationofculturing, the culturein eachbottlewas frozen and thawed to prepare a virus suspension, which was then pooled.
- 10 Thereafter, the virus suspension was centri~uged (3,000 rpm, 10 minutes), to recover the supernatant (800 ml per one culture), which was defined as a crudely purified virus suspension. The virus infectious titer (X106 FFU/ml) of each of the individually crudely purified virus suspensions, recovered through culture eight times in total, was assayed in the same manner as described in F.~c~mpl e 3, (3~. Consequently, the resulting titers in log (FFU/ml) were 4.9, 5.5, 10.0, 7.0, 7.5, 8.0, 4.2 and 4Ø
(2) Purification of AU64n strain virus By using the crudely purified virus suspensions, 4 lots were prepared in total, each lot of 1.2 liters. The virus of each lot was purified as follows. The crudely purified virus suspension ofeachlotwas centrifuged (10,000 rpmforlOminutes), and the resulting supernatant was collected, followed by further 25 ultracentrifugation (19,000 rpm, 6 hours), and the precipitate was suspended in 15 mM PBS, pH 7.5, to a final volume of 40 ml, which was a 30-fold ~nnc~ntrated solution. The concentrated solution was centrifuged (10,000 rpm, 10 minutes), and the supernatant was collected, which was then overlaid on a 30 (W/V) %
sucrose cushion, for ultracentrifugation (38,000 rpm, 3 hours).
After ultracentrifugation, the resulting precipitated fraction was again suspended in 15 mM PBS, pH 7.5, to recover the virus of a purified AU64n strain. The virus infectious titers of the 4 lots in total in re-suspension (6 ml/lot) were counted;
- 10 simultaneously, the protein was assayed by the phenol reagent method. Consequently, the virus infectious titer (XlO~PFU/ml) and [protein level (mg/ml)] were as follows; 3.8 [1.36] for #1;
4.8 [1.10] for #2; 3.3 [0.94] for ~3; and 1.3[1.57] for #4.
(3) Inactivation of AU64n strain virus From the individual lots (#1 through #4) were collected the re-suspension solutions (purified AU64n strain virus), each of 3 ml, and the pooled re-suspensions in total of 12 ml were diluted and adjusted with 15 mM PBS, pH 7.5 to a protein content of 100 ~ g/ml protein, followed by addition of formalin to a final concentration o~ 0.1 (V~V) %, and the resulting solution was left to stand at 4 &~ for 2 weeks. Then, the solution was dialyzed against 15 mM PBS, pH 7.5 at 5 ~ for 30 hours. So as to verify the appropriateness of theinactivated virus-containing solution after completion of the dialysis as an inactivated rotavaccine bulk solution, a variety of tests were carried out.
According to the Regulation "J~p~n~se B Encephalitis Vaccine"
definedin theBiological Fo~mll~tionStandard,morespecifically, protein content tests, coloring tests, sterile tests, inactivation tests and tests of the absence of abnormal toxicity were done, provided that the inactivation tests were conducted by using Vero CL-9 cells. Consequently, it was verified that the inactivated virus-containing solution was suitable as a vaccine bulk solution.
(4) Preparation of vaccine ~g~inst rotavirus infections The vaccine bulk solution was diluted with 15 mM PBS, pH
7.5, to adjust the protein content to 50 ~ g/ml, to prepare an inactivated AU64n v~c~in~. Meanwhile, 0.5 ml was collected from each of the non-inactivated 4 lots, and the pooled re-suspensions (purified AU64n strain virus) were adjusted to 50 ~ g/ml in the same manner as described above, and the resulting solution was defined as raw AU64n-cont~ining solution.
(5) Assaying of immunogenicity of inactivated AU64n vaccine The inactivated AU64n vaccine was inoculated twice at a dose of 10 ~ g protein/dose into ddy mice of age 4 - 5 weeks (7 animals) at an interval of 2 weeks, and on week 2, blood was drawn.
As ~om~rative controls, a raw AU64n-containing solution and 15 mM PBS, pH 7.5 both were used; the former was inoculated into 19 mice and the latter, into 10 mice, prior to blood collection. The neutralization antibody titer of each serum recovered for the AU64n strain was assayed by the 60 ~ plaque reduction method. The results are shown in Table 3, which verifies the ~c~llent immunogenicity of the resulting vaccine.
Table 3 Antigen for i~munization Neutralization antibody titer +
confidence limits Inactivated AU64n vaccine 2.20 + 0.23 Raw AU64n-containing solution 2.30 + O.12 15 mM PBS, pH 7.5 < 1.60 Neutralization antibody titer: geometric mean of antibody titers in common log of individual mice Confidence limits: significance level 5 %
(6) Tmml-nization performance of inactivated AU64n vaccine By the 60 % focus reduction method, the neutralization potency of the sera from 7 mice immunized with the inactivated AU64n vaccine against rotaviruses with different serotypes or genotypes was assayed. The results are shown in Table 4. It was indicated that the vaccine prepared by using the AU64n strain as the effective component showed efficiency for prevention against the infection not only with the AU64n strain but also with astrain Wa, with difference in both Serotype P and genotype from those of the strain, and a DS-1 strain with a different serotype G
Table 4 Challenge virus Serotypes P and G Neutralization antibody [genotypes] + con~idence limits AU64n GlPlB[4] 2.19 + O.52 wa GlPlA[8] 2.43 + 0.43 DS-l G2P13[4] . 1.90 + 0.25 Neutralization antibody titer: geometric mean of antibody titers in common log of individual mice Confidence limits: significance level 5 F~m~le 5 Recovery of novel human rotavirus strain AU32n:
By the same method as described in F.~r~rn~l e 3, a novel human rotavirus strain was isolatedandpassaged to assay theinfectious titer and analyze the serotype and genotype. More specifically, by using A~MK cells, human rotavirus strains were separated from diarrhea feces from a rotavirus-infected infant, and after the passage in the same cells over two generations, the strains were passaged in Vero CL-9 cells over 8 generations in total [first to third generations (plaque cloning), fourth generation (stationary culture), fifth generation (plaque cloning), sixth generation (stationary culture), seventh to eighth generations (roller bottle culture)], to recover a cloned cell-adapted human rotavirus strain ~passage history is AGMK/3, Vero CL-9/8). The infectivity titer of the human rotavirus strain was 6.0 in log (FFU/ml). And, its serotype [genotype] was G9PlA [8], which was the same as those o~ the AU32 strain. Thus, the novel hum n rotavirus strain was designated as AU32n.
F.~mple 6 Isolation of rotavirus in Vero CL-9:
By the same method as described in Example 3~1), rotavirus is to be isolated. However, the isolation procedure is carried - 10 out by using Vero CL-9 cells in place of AGMK cells.
Tn~llctrial Appli~hility The present invention provides a vaccine, a diagnostic agent, and a reagent, all relating to rotavirus infections, and methods forproducing them, whereby thepresentinvention canmake contributions to human health, worldwide medical administrative management, environmental hygiene, cattle raising, and research works for the flln~m~ntals and clinical practice and application of rotavirus infections. The present invention provides a vaccine as a strong prophylactic means against diseases drawing serious concern under the names of infant vomiting and diarrhea, white feces diarrhea, infantpseudo-cholera and the like. Hence, the present invention can give welfare expected for a long term, not only to individual homes worldwide but also to individual workers engaged in medicine and health care all around the world.
Table 4 Challenge virus Serotypes P and G Neutralization antibody [genotypes] + con~idence limits AU64n GlPlB[4] 2.19 + O.52 wa GlPlA[8] 2.43 + 0.43 DS-l G2P13[4] . 1.90 + 0.25 Neutralization antibody titer: geometric mean of antibody titers in common log of individual mice Confidence limits: significance level 5 F~m~le 5 Recovery of novel human rotavirus strain AU32n:
By the same method as described in F.~r~rn~l e 3, a novel human rotavirus strain was isolatedandpassaged to assay theinfectious titer and analyze the serotype and genotype. More specifically, by using A~MK cells, human rotavirus strains were separated from diarrhea feces from a rotavirus-infected infant, and after the passage in the same cells over two generations, the strains were passaged in Vero CL-9 cells over 8 generations in total [first to third generations (plaque cloning), fourth generation (stationary culture), fifth generation (plaque cloning), sixth generation (stationary culture), seventh to eighth generations (roller bottle culture)], to recover a cloned cell-adapted human rotavirus strain ~passage history is AGMK/3, Vero CL-9/8). The infectivity titer of the human rotavirus strain was 6.0 in log (FFU/ml). And, its serotype [genotype] was G9PlA [8], which was the same as those o~ the AU32 strain. Thus, the novel hum n rotavirus strain was designated as AU32n.
F.~mple 6 Isolation of rotavirus in Vero CL-9:
By the same method as described in Example 3~1), rotavirus is to be isolated. However, the isolation procedure is carried - 10 out by using Vero CL-9 cells in place of AGMK cells.
Tn~llctrial Appli~hility The present invention provides a vaccine, a diagnostic agent, and a reagent, all relating to rotavirus infections, and methods forproducing them, whereby thepresentinvention canmake contributions to human health, worldwide medical administrative management, environmental hygiene, cattle raising, and research works for the flln~m~ntals and clinical practice and application of rotavirus infections. The present invention provides a vaccine as a strong prophylactic means against diseases drawing serious concern under the names of infant vomiting and diarrhea, white feces diarrhea, infantpseudo-cholera and the like. Hence, the present invention can give welfare expected for a long term, not only to individual homes worldwide but also to individual workers engaged in medicine and health care all around the world.
Claims (12)
1. A method for producing a rotavirus antigen, which comprises:
cloning a cell highly permitting the proliferation of rotavirus from a cell culture;
preparing a cloned cell adapted-rotavirus strain by passaging a rotavirus in the resulting cloned cell strain and adapting the rotavirus to the cloned cell strain;
culturing as a seed virus the adapted rotavirus strain or a reassortant prepared by using the adapted rotavirus strain as a parent strain; and isolating and purifying the rotavirus antigen from the culture medium of the seed virus.
cloning a cell highly permitting the proliferation of rotavirus from a cell culture;
preparing a cloned cell adapted-rotavirus strain by passaging a rotavirus in the resulting cloned cell strain and adapting the rotavirus to the cloned cell strain;
culturing as a seed virus the adapted rotavirus strain or a reassortant prepared by using the adapted rotavirus strain as a parent strain; and isolating and purifying the rotavirus antigen from the culture medium of the seed virus.
2. The method according to claim 1, wherein the cell culture is Vero cell (ATCC CCL 81).
3. The method according to claim 1 or 2, wherein the cloned cell strain is Vero CL-9 (FERM BP-6028).
4. The method according to any one of claims 1 to 3, wherein the rotavirus is human rotavirus strain AU32n and/or AU64n.
5. A rotavirus antigen recovered by the method according to any one of claims 1 to 4.
6. An inactivated antigen prepared by further inactivating the rotavirus antigen of claim 5 with an inactivating agent.
7. A vaccine for rotavirus infections, containing the rotavirus antigen of claim 5 or the inactivated antigen of claim 6 at an amount for causing an immune response.
8. A combined multivalent vaccine for rotavirus infections, containing two or more antigens at an amount required for an immune response, wherein the antigens are the rotavirus antigen of claim 5 or the inactivated antigen of claim 6, and the serotypes or genotypes thereof are different from each other.
9. A diagnostic agent, containing the rotavirus antigen of claim 5 or the inactivated antigen of claim 6 at an amount required for an antigen-antibody response.
10. Cloned cell strain Vero Cl-9 (FERM BP-6028).
11. Cloned cell adapted-human rotavirus strain AU32n.
12. Cloned cell adapted-human rotavirus strain AU64n.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP312547/1996 | 1996-10-18 | ||
| JP31254796 | 1996-10-18 | ||
| PCT/JP1997/003777 WO1998017785A1 (en) | 1996-10-18 | 1997-10-20 | Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2240843A1 true CA2240843A1 (en) | 1998-04-30 |
Family
ID=29404531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2240843 Abandoned CA2240843A1 (en) | 1996-10-18 | 1997-10-20 | Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2240843A1 (en) |
-
1997
- 1997-10-20 CA CA 2240843 patent/CA2240843A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0601062B1 (en) | Sirs vaccine and diagnosis method | |
| US6498008B2 (en) | Method for detecting swine infertility and respiratory virus | |
| US7264804B2 (en) | Kits for detecting anti-SIRS antibodies | |
| FI117513B (en) | Process for the cultivation of PRRS virus and its use in vaccines | |
| US6110724A (en) | Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen | |
| US6080570A (en) | Method of producing a vaccine for Swine Infertility and Respiratory Syndrome | |
| WO1993006211A1 (en) | Vaccine for mystery swine disease and method for diagnosis thereof | |
| CN105866408B (en) | A kind of four kinds of enterovirus joint-detection immune chromatography reagent kits and preparation method thereof | |
| US5283172A (en) | Type-C rotavirus cultures and uses therefor | |
| Tsuda et al. | Competitive enzyme-linked immunosorbent assay for the detection of the antibodies specific to Akabane virus | |
| CA2240843A1 (en) | Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same | |
| EP0502107B1 (en) | Type-b rotavirus cultures and uses thereof | |
| Beards et al. | Homotypic and heterotypic immune responses to group A rotaviruses in parenterally immunized sheep | |
| Flewett et al. | Recent advances in the study of viral gastroenteritis | |
| Gaul | Antigenic studies of animal rotaviruses: relationships by virus neutralization in vitro and cross-protection in gnotobiotic piglets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |